Featured
15th Annual Conference of the SSBMT / EBMT Highlights
15th Annual Conference of the SSBMT / EBMT Highlights & the 13th Annual Saudi Hem/Onc Nurses Conference Event Dates: 15 May 2026 - 16 May 2026 To review program: https://tawasolevents.com/15ssbmt.pdf ------ This video covers the 15th Annual Conference of the SSBMT (Saudi Society of Blood and Marrow Transplantation) and EBMT (European Society for Blood and Marrow Transplantation) Highlights, held from May 15–16, 2026. The program features various sessions focusing on hematopoietic cell transplantation, cellular and gene therapy, and nursing education in these specialized fields. Key Highlights So Far (0:00 - 6:15:32): Introduction to SSBMT: The conference began with an introduction to the SSBMT, emphasizing its role in advancing transplantation science and international collaboration with the EBMT (19:53 - 21:44). Transplant Medicine & Novel Agents: Experts discussed the use of ATG (Anti-thymocyte globulin) and immunosuppressive strategies post-transplant (55:34 - 1:01:12). Insights were provided on integrating novel agents and allogeneic transplant in myelofibrosis treatment (1:01:20 - 1:34:47). The management of PNH (Paroxysmal Nocturnal Hemoglobinuria) and the role of complement inhibitors were reviewed (1:34:55 - 2:01:05). Gene Therapy Updates: A session on gene editing for sickle cell disease and transfusion-dependent thalassemia showcased significant improvements in patient outcomes, including high rates of freedom from vaso-occlusive crises (2:46:14 - 3:12:00). Transplant-Associated Complications: Presentations covered managing HLH (Hemophagocytic Lymphohistiocytosis) after CAR-T therapy (3:15:10 - 3:40:22) and understanding TA-TMA (Transplant-Associated Thrombotic Microangiopathy), highlighting the importance of early detection and complement-mediated management (3:40:28 - 3:57:51). Nursing Education & Professional Development: The EBMT nurses group highlighted their new certification exam and educational resources available for transplant nurses (5:22:15 - 5:35:15). Awards were presented for the best abstracts in adult and pediatric nursing research (5:35:40 - 5:49:15). Sessions explored the impact of novel therapies on nursing education and the necessity of tailored, competency-based training strategies (6:18:37 - 6:39:52). Continuing Content: The latter part of the video includes sessions on sickle cell transplant rates (7:26:16 - 7:43:18) and nursing experiences with cellular and bispecific antibody therapies (7:43:23 onwards), followed by discussions on expanding bone marrow transplant access to support Saudi Arabia's Vision 2030 (8:23:51 onwards).
15th Annual Conference of the SSBMT/ EBMT 2026 2026 Conference 3 videos
15th Annual Conference of the SSBMT / EBMT Highlights
General
15th Annual Conference of the SSBMT / EBMT Highlights
Watched
General
2026
15th Annual Conference of the SSBMT / EBMT Highlights
15th Annual Conference of the SSBMT / EBMT Highlights
Conference
15th Annual Conference of the SSBMT / EBMT Highlights
Watched
Conference
2026
15th Annual Conference of the SSBMT / EBMT Highlights
15th Annual Conference of the SSBMT / EBMT Highlights
Conference
15th Annual Conference of the SSBMT / EBMT Highlights
Watched
Conference
2026
15th Annual Conference of the SSBMT / EBMT Highlights
Fourth SSBMT & SSH Combined Annual Conference 2026 Conference 22 videos
Lymphoma mimickers & Diagnostic Traps | Alfadel Alshaibani | 31 JAN 2026
General
Lymphoma mimickers & Diagnostic Traps | Alfadel Alshaibani | 31 JAN 2026
Watched
General
2026
Lymphoma mimickers & Diagnostic Traps | Alfadel Alshaibani | 31 JAN 2026
Overview on Platelets Products in Clinical Practice | Salwa Hindawi | 31 JAN 2026
General
Overview on Platelets Products in Clinical Practice | Salwa Hindawi | 31 JAN 2026
Watched
General
2026
Overview on Platelets Products in Clinical Practice | Salwa Hindawi | 31 JAN 2026
Cancer Associated Thrombosis (CAT) | Sarah Sewaralthahab | 31 JAN 2026
General
Cancer Associated Thrombosis (CAT) | Sarah Sewaralthahab | 31 JAN 2026
Watched
General
2026
Cancer Associated Thrombosis (CAT) | Sarah Sewaralthahab | 31 JAN 2026
Complicated cases of thrombosis – challenges in management | Ashraf Warsi | 31 JAN 2026
General
Complicated cases of thrombosis – challenges in management | Ashraf Warsi | 31 JAN 2026
Watched
General
2026
Complicated cases of thrombosis – challenges in management | Ashraf Warsi | 31 JAN 2026
Richter’s Transformation | Mohammed Almakadi | 31 JAN 2026
General
Richter’s Transformation | Mohammed Almakadi | 31 JAN 2026
Watched
General
2026
Richter’s Transformation | Mohammed Almakadi | 31 JAN 2026
Hodgkin Lymphoma–therapy sequencing in the era of upfront biologic therapy |Ahmed Barefah |31JAN2026
General
Hodgkin Lymphoma–therapy sequencing in the era of upfront biologic therapy |Ahmed Barefah |31JAN2026
Watched
General
2026
Hodgkin Lymphoma–therapy sequencing in the era of upfront biologic therapy |Ahmed Barefah |31JAN2026
Fixed duration Novel agents’ combinations in CLL upfront therapy | Ahmed Absi | 31 JAN 2026
General
Fixed duration Novel agents’ combinations in CLL upfront therapy | Ahmed Absi | 31 JAN 2026
Watched
General
2026
Fixed duration Novel agents’ combinations in CLL upfront therapy | Ahmed Absi | 31 JAN 2026
Neutrophilia other than CML | Hanan Hamed | 31 JAN 2026
General
Neutrophilia other than CML | Hanan Hamed | 31 JAN 2026
Watched
General
2026
Neutrophilia other than CML | Hanan Hamed | 31 JAN 2026
GVHD 2025: New Predictive Biomarkers and Treatment Algorithms | Naif Aljohani | 30 JAN 2026
General
GVHD 2025: New Predictive Biomarkers and Treatment Algorithms | Naif Aljohani | 30 JAN 2026
Watched
General
2026
GVHD 2025: New Predictive Biomarkers and Treatment Algorithms | Naif Aljohani | 30 JAN 2026
MPNs: JAK Inhibitors vs New Pathway Inhibitors— When to Switch Therapy | Sultan Altouri |30 JAN 2026
General
MPNs: JAK Inhibitors vs New Pathway Inhibitors— When to Switch Therapy | Sultan Altouri |30 JAN 2026
Watched
General
2026
MPNs: JAK Inhibitors vs New Pathway Inhibitors— When to Switch Therapy | Sultan Altouri |30 JAN 2026
CML 2025:Achieving Treatment-Free Remission—Patient Selection Algorithm | Ihab Elhemaidi |30JAN 2026
General
CML 2025:Achieving Treatment-Free Remission—Patient Selection Algorithm | Ihab Elhemaidi |30JAN 2026
Watched
General
2026
CML 2025:Achieving Treatment-Free Remission—Patient Selection Algorithm | Ihab Elhemaidi |30JAN 2026
Challenges in Thalassemia for Precision Medicine: Evidence Based Research| Soad Aljaouni|30 JAN 2026
General
Challenges in Thalassemia for Precision Medicine: Evidence Based Research| Soad Aljaouni|30 JAN 2026
Watched
General
2026
Challenges in Thalassemia for Precision Medicine: Evidence Based Research| Soad Aljaouni|30 JAN 2026
Emerging Therapies in β-Thalassemia — Luspatercept and Beyond | Abdullah Alzayed | 30 JAN 2026
General
Emerging Therapies in β-Thalassemia — Luspatercept and Beyond | Abdullah Alzayed | 30 JAN 2026
Watched
General
2026
Emerging Therapies in β-Thalassemia — Luspatercept and Beyond | Abdullah Alzayed | 30 JAN 2026
Managing Challenging Cases: Sickle Cell disease | Gad Allah Ali | 30 JAN 2026
General
Managing Challenging Cases: Sickle Cell disease | Gad Allah Ali | 30 JAN 2026
Watched
General
2026
Managing Challenging Cases: Sickle Cell disease | Gad Allah Ali | 30 JAN 2026
Gene Therapy for SCD and TDT — Clinical and Economic Reality | Mohsen Alzahrani | 30 JAN 2026
General
Gene Therapy for SCD and TDT — Clinical and Economic Reality | Mohsen Alzahrani | 30 JAN 2026
Watched
General
2026
Gene Therapy for SCD and TDT — Clinical and Economic Reality | Mohsen Alzahrani | 30 JAN 2026
Gene Therapies: A New Era in Hemoglobinopathies | Ihab Elehmaidi | 30 JAN 2026
General
Gene Therapies: A New Era in Hemoglobinopathies | Ihab Elehmaidi | 30 JAN 2026
Watched
General
2026
Gene Therapies: A New Era in Hemoglobinopathies | Ihab Elehmaidi | 30 JAN 2026
Emerging role of BCMA targeting in management of RRMM | Ghazi Alotaibi | 30 JAN 2026
General
Emerging role of BCMA targeting in management of RRMM | Ghazi Alotaibi | 30 JAN 2026
Watched
General
2026
Emerging role of BCMA targeting in management of RRMM | Ghazi Alotaibi | 30 JAN 2026
Plasma Cell Leukemia – Update on therapy SOC | Majed Alahmadi | 30 JAN 2026
General
Plasma Cell Leukemia – Update on therapy SOC | Majed Alahmadi | 30 JAN 2026
Watched
General
2026
Plasma Cell Leukemia – Update on therapy SOC | Majed Alahmadi | 30 JAN 2026
MRD Negativity in Multiple Myeloma: A New Treatment Endpoint| Ghazi Alotaibi | 30 JAN 2026
General
MRD Negativity in Multiple Myeloma: A New Treatment Endpoint| Ghazi Alotaibi | 30 JAN 2026
Watched
General
2026
MRD Negativity in Multiple Myeloma: A New Treatment Endpoint| Ghazi Alotaibi | 30 JAN 2026
CAR-T vs Bispecific Antibodies in Myeloma—Bridging Strategies& supportive measures|Abdullah Alsaleh
General
CAR-T vs Bispecific Antibodies in Myeloma—Bridging Strategies& supportive measures|Abdullah Alsaleh
Watched
General
2026
CAR-T vs Bispecific Antibodies in Myeloma—Bridging Strategies& supportive measures|Abdullah Alsaleh
Combined SSBMT & SSH Annual Conference JAN 30-31 2026
Live
Combined SSBMT & SSH Annual Conference JAN 30-31 2026
Watched
Live
2026
Combined SSBMT & SSH Annual Conference JAN 30-31 2026
SSBMT & SSH COMBINED ANNUAL CONFERENCE 30-31 JAN 2026
Conference
SSBMT & SSH COMBINED ANNUAL CONFERENCE 30-31 JAN 2026
Watched
Conference
2026
SSBMT & SSH COMBINED ANNUAL CONFERENCE 30-31 JAN 2026
14th Annual Conference of the SSBMT 2026 Conference 1 video
Eosinophilic Updates to Old Approaches | Osman Radhwi | 30 JAN 2026
General
Eosinophilic Updates to Old Approaches | Osman Radhwi | 30 JAN 2026
Watched
General
2026
Eosinophilic Updates to Old Approaches | Osman Radhwi | 30 JAN 2026
13th Annual Conference of the SSBMT 2024 Conference 1 video
SSBMT & SSH COMBINED ANNUAL CONFERENCE
Conference
SSBMT & SSH COMBINED ANNUAL CONFERENCE
Watched
Conference
2024
SSBMT & SSH COMBINED ANNUAL CONFERENCE
Second SSBMT/SSH Combined Annual Conference 2024 Conference 2 videos
SSBMT & SSH COMBINED ANNUAL CONFERENCE
General
SSBMT & SSH COMBINED ANNUAL CONFERENCE
Watched
General
2024
SSBMT & SSH COMBINED ANNUAL CONFERENCE
SSBMT & SSH COMBINED ANNUAL CONFERENCE
General
SSBMT & SSH COMBINED ANNUAL CONFERENCE
Watched
General
2024
SSBMT & SSH COMBINED ANNUAL CONFERENCE
SSBMT Webinar Series - 18 April 2026
Webinar
SSBMT Webinar Series - 18 April 2026
Watched
Webinar
2026
SSBMT Webinar Series - 18 April 2026
CAR-T vs Bispecific Antibodies in Aggressive Lymphoma | Sameer Alamoudi | 30 JAN 2026
General
CAR-T vs Bispecific Antibodies in Aggressive Lymphoma | Sameer Alamoudi | 30 JAN 2026
Watched
General
2026
CAR-T vs Bispecific Antibodies in Aggressive Lymphoma | Sameer Alamoudi | 30 JAN 2026
Philadelphia positive ALL -Best First Line Therapy | Nahla Shihata | 30 JAN 2026
General
Philadelphia positive ALL -Best First Line Therapy | Nahla Shihata | 30 JAN 2026
Watched
General
2026
Philadelphia positive ALL -Best First Line Therapy | Nahla Shihata | 30 JAN 2026
1 Integration of Menin Inhibitors in the therapy of AML | Muteb Althomali | | 30 JAN 2026
General
1 Integration of Menin Inhibitors in the therapy of AML | Muteb Althomali | | 30 JAN 2026
Watched
General
2026
1 Integration of Menin Inhibitors in the therapy of AML | Muteb Althomali | | 30 JAN 2026
ALL:How does the future look like w/ Incorporation of upfront Novel therapies | Saleem Eldadah
General
ALL:How does the future look like w/ Incorporation of upfront Novel therapies | Saleem Eldadah
Watched
General
2026
ALL:How does the future look like w/ Incorporation of upfront Novel therapies | Saleem Eldadah
Frontline Management in Multiple Myeloma | Ayman Alhejazi | 30 JAN 2026
General
Frontline Management in Multiple Myeloma | Ayman Alhejazi | 30 JAN 2026
Watched
General
2026
Frontline Management in Multiple Myeloma | Ayman Alhejazi | 30 JAN 2026
HIV Associated Lymphomas | Hafiz Malhan | 30 JAN 2026
General
HIV Associated Lymphomas | Hafiz Malhan | 30 JAN 2026
Watched
General
2026
HIV Associated Lymphomas | Hafiz Malhan | 30 JAN 2026
Is there still a role for ASCT in Mantle Cell Lymphoma | Reyad Dada | 30 JAN 2026
General
Is there still a role for ASCT in Mantle Cell Lymphoma | Reyad Dada | 30 JAN 2026
Watched
General
2026
Is there still a role for ASCT in Mantle Cell Lymphoma | Reyad Dada | 30 JAN 2026
Now Is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma | Mubarak Almansour| 30JAN 2026
General
Now Is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma | Mubarak Almansour| 30JAN 2026
Watched
General
2026
Now Is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma | Mubarak Almansour| 30JAN 2026
SSBMT Webinar Series - Role of Tecartus in MCL and ALL - 27 December 2025
Webinar
SSBMT Webinar Series - Role of Tecartus in MCL and ALL - 27 December 2025
Watched
Webinar
2025
SSBMT Webinar Series - Role of Tecartus in MCL and ALL - 27 December 2025
AI in Healthcare Webinar - MDS – A complex disease but should it remain as such?
Webinar
AI in Healthcare Webinar - MDS – A complex disease but should it remain as such?
Watched
Webinar
2025
AI in Healthcare Webinar - MDS – A complex disease but should it remain as such?
SSBMT Webinar Series - Yescarta in Real-World Evidence (RWE) - 08 November 2025
Webinar
SSBMT Webinar Series - Yescarta in Real-World Evidence (RWE) - 08 November 2025
Watched
Webinar
2025
SSBMT Webinar Series - Yescarta in Real-World Evidence (RWE) - 08 November 2025
SSBMT Webinar Series - Long-Term Follow-Up and Safety Management for Axi-Cel - 25 October 2025
Webinar
SSBMT Webinar Series - Long-Term Follow-Up and Safety Management for Axi-Cel - 25 October 2025
Watched
Webinar
2025
SSBMT Webinar Series - Long-Term Follow-Up and Safety Management for Axi-Cel - 25 October 2025
SSBMT Webinar Series (CAR T-Cell Therapy) - 14 October 2025
Webinar
SSBMT Webinar Series (CAR T-Cell Therapy) - 14 October 2025
Watched
Webinar
2025
SSBMT Webinar Series (CAR T-Cell Therapy) - 14 October 2025
AI in Healthcare Webinar Series - 11 October 2025 "AI Role in post-transplant complications/GVHD"
Webinar
AI in Healthcare Webinar Series - 11 October 2025 "AI Role in post-transplant complications/GVHD"
Watched
Webinar
2025
AI in Healthcare Webinar Series - 11 October 2025 "AI Role in post-transplant complications/GVHD"
Day 2 18-ICML Highlights & Hematopathology Overview
General
Day 2 18-ICML Highlights & Hematopathology Overview
Watched
General
2025
Day 2 18-ICML Highlights & Hematopathology Overview
18-ICML Highlights & Hematopathology Overview
General
18-ICML Highlights & Hematopathology Overview
Watched
General
2025
18-ICML Highlights & Hematopathology Overview
AI in Healthcare Webinar Series - 13 September 2025
Webinar
AI in Healthcare Webinar Series - 13 September 2025
Watched
Webinar
2025
AI in Healthcare Webinar Series - 13 September 2025
AI in Healthcare Webinar Series - 16 August 2025
Webinar
AI in Healthcare Webinar Series - 16 August 2025
Watched
Webinar
2025
AI in Healthcare Webinar Series - 16 August 2025
AI in Healthcare Webinar Series - 19 July 2025
Webinar
AI in Healthcare Webinar Series - 19 July 2025
Watched
Webinar
2025
AI in Healthcare Webinar Series - 19 July 2025
07 Novel approaches for primary refractory DLBCL management | Dr . Bader Alahmari | 14 Sept 2024
General
07 Novel approaches for primary refractory DLBCL management | Dr . Bader Alahmari | 14 Sept 2024
Watched
General
2025
07 Novel approaches for primary refractory DLBCL management | Dr . Bader Alahmari | 14 Sept 2024
06 HSCT – local experience – EGYPT | Dr. Almetwaly Sultan | 14 Sept 2024
General
06 HSCT – local experience – EGYPT | Dr. Almetwaly Sultan | 14 Sept 2024
Watched
General
2025
06 HSCT – local experience – EGYPT | Dr. Almetwaly Sultan | 14 Sept 2024
05 HSCT – local experience – OMAN | Dr. Thuraya Al-Busaidi | 14 Sept 2024
General
05 HSCT – local experience – OMAN | Dr. Thuraya Al-Busaidi | 14 Sept 2024
Watched
General
2025
05 HSCT – local experience – OMAN | Dr. Thuraya Al-Busaidi | 14 Sept 2024
04 Strategies and challenges in R/R AML | Dr. Bader Alahmari | 14 Sept 2024
General
04 Strategies and challenges in R/R AML | Dr. Bader Alahmari | 14 Sept 2024
Watched
General
2025
04 Strategies and challenges in R/R AML | Dr. Bader Alahmari | 14 Sept 2024
03 Practical consideration in the management of DLBCL patients | Dr. David Lewis | 14 Sept 2024
General
03 Practical consideration in the management of DLBCL patients | Dr. David Lewis | 14 Sept 2024
Watched
General
2025
03 Practical consideration in the management of DLBCL patients | Dr. David Lewis | 14 Sept 2024
08 CAR T-cell Therapy – Local experience (KFSH&RC) | Dr. Ibrahim Al Ghemlas | 14 Sept 2024
General
08 CAR T-cell Therapy – Local experience (KFSH&RC) | Dr. Ibrahim Al Ghemlas | 14 Sept 2024
Watched
General
2025
08 CAR T-cell Therapy – Local experience (KFSH&RC) | Dr. Ibrahim Al Ghemlas | 14 Sept 2024
09 Auto-HCT in MM | Dr. Meral Beksac | 14 September 2024
General
09 Auto-HCT in MM | Dr. Meral Beksac | 14 September 2024
Watched
General
2025
09 Auto-HCT in MM | Dr. Meral Beksac | 14 September 2024
12 International recommendations for screening and preventative practices | Dr. Neel Bhatt|14Sep2024
General
12 International recommendations for screening and preventative practices | Dr. Neel Bhatt|14Sep2024
Watched
General
2025
12 International recommendations for screening and preventative practices | Dr. Neel Bhatt|14Sep2024
10 ASTCT Clinical Practice Recommendations | Dr. Narendranath Epperla | 14 Sept 2024
General
10 ASTCT Clinical Practice Recommendations | Dr. Narendranath Epperla | 14 Sept 2024
Watched
General
2025
10 ASTCT Clinical Practice Recommendations | Dr. Narendranath Epperla | 14 Sept 2024
11 Gene editing and gene therapy for haemoglobinopathies | Dr. Haydar Frangoul | 14 Sept 2024
General
11 Gene editing and gene therapy for haemoglobinopathies | Dr. Haydar Frangoul | 14 Sept 2024
Watched
General
2025
11 Gene editing and gene therapy for haemoglobinopathies | Dr. Haydar Frangoul | 14 Sept 2024
01 Preventing post-transplant relapse in AML | Dr. Ali Bazarbachi | 13 Sept 2024
General
01 Preventing post-transplant relapse in AML | Dr. Ali Bazarbachi | 13 Sept 2024
Watched
General
2025
01 Preventing post-transplant relapse in AML | Dr. Ali Bazarbachi | 13 Sept 2024
06 HSCT in sickle cell disease "update" and local MNGHA-R experience | Dr. Mohammed Essa|13 Sep 2024
General
06 HSCT in sickle cell disease "update" and local MNGHA-R experience | Dr. Mohammed Essa|13 Sep 2024
Watched
General
2025
06 HSCT in sickle cell disease "update" and local MNGHA-R experience | Dr. Mohammed Essa|13 Sep 2024
05 GVHD: from prophylaxis to therapy: 10 years of progress | Dr. Mohammad Mohty | 13 Sept 2024
General
05 GVHD: from prophylaxis to therapy: 10 years of progress | Dr. Mohammad Mohty | 13 Sept 2024
Watched
General
2025
05 GVHD: from prophylaxis to therapy: 10 years of progress | Dr. Mohammad Mohty | 13 Sept 2024
03 Taking a BiTE out of Lymphoma: Bispecific Antibodies in DLBCL | Dr David Lewis | 13 Sept 2024
General
03 Taking a BiTE out of Lymphoma: Bispecific Antibodies in DLBCL | Dr David Lewis | 13 Sept 2024
Watched
General
2025
03 Taking a BiTE out of Lymphoma: Bispecific Antibodies in DLBCL | Dr David Lewis | 13 Sept 2024
04 GVHD – local experience | Dr. Bader Alahmari | 13 Sept 2024
General
04 GVHD – local experience | Dr. Bader Alahmari | 13 Sept 2024
Watched
General
2025
04 GVHD – local experience | Dr. Bader Alahmari | 13 Sept 2024
02 Chemo-free therapy in Ph-positive ALL | Dr. Hind Salama | 13 Sept 2024
General
02 Chemo-free therapy in Ph-positive ALL | Dr. Hind Salama | 13 Sept 2024
Watched
General
2025
02 Chemo-free therapy in Ph-positive ALL | Dr. Hind Salama | 13 Sept 2024
10 Future Development of CAR T | Dr. Michael Hudecek | 13 Sept 2024
General
10 Future Development of CAR T | Dr. Michael Hudecek | 13 Sept 2024
Watched
General
2025
10 Future Development of CAR T | Dr. Michael Hudecek | 13 Sept 2024
09 Optimizing Transplant Outcomes for High-Risk MDS | Dr. Pramila Krishnamurthy | 13 Sept 2024
General
09 Optimizing Transplant Outcomes for High-Risk MDS | Dr. Pramila Krishnamurthy | 13 Sept 2024
Watched
General
2025
09 Optimizing Transplant Outcomes for High-Risk MDS | Dr. Pramila Krishnamurthy | 13 Sept 2024
08 Gene - edited Therapy Saudi Experience in TDT and SCD | Dr. Mohammed Essa | 13 Sept 2024
General
08 Gene - edited Therapy Saudi Experience in TDT and SCD | Dr. Mohammed Essa | 13 Sept 2024
Watched
General
2025
08 Gene - edited Therapy Saudi Experience in TDT and SCD | Dr. Mohammed Essa | 13 Sept 2024
07 Gene Therapies: A New Era for Hemoglobinopathies | Dr. Abdullah Al Jefri | 13 Sept 2024
General
07 Gene Therapies: A New Era for Hemoglobinopathies | Dr. Abdullah Al Jefri | 13 Sept 2024
Watched
General
2025
07 Gene Therapies: A New Era for Hemoglobinopathies | Dr. Abdullah Al Jefri | 13 Sept 2024
05 Updates in cutaneous lymphomas | Dr. Tariq Alzaid | 26 Oct 2025
General
05 Updates in cutaneous lymphomas | Dr. Tariq Alzaid | 26 Oct 2025
Watched
General
2025
05 Updates in cutaneous lymphomas | Dr. Tariq Alzaid | 26 Oct 2025
04 Bone marrow evaluation in lymphoma | Dr. Khaled Alayed | 26 Oct 2024
General
04 Bone marrow evaluation in lymphoma | Dr. Khaled Alayed | 26 Oct 2024
Watched
General
2025
04 Bone marrow evaluation in lymphoma | Dr. Khaled Alayed | 26 Oct 2024
03 Molecular diagnostic advances in lymphoma | Dr. Abdullah Alswaidan | 26 Oct 2024
General
03 Molecular diagnostic advances in lymphoma | Dr. Abdullah Alswaidan | 26 Oct 2024
Watched
General
2025
03 Molecular diagnostic advances in lymphoma | Dr. Abdullah Alswaidan | 26 Oct 2024
02 Role of C-MYC in lymphoid neoplasms | Dr. Nasir Bakhshi | 26 Oct 2024
General
02 Role of C-MYC in lymphoid neoplasms | Dr. Nasir Bakhshi | 26 Oct 2024
Watched
General
2025
02 Role of C-MYC in lymphoid neoplasms | Dr. Nasir Bakhshi | 26 Oct 2024
01 Role of CD30 in hematolymphoid malignancies | Dr. Saeed Alshieban | 26 Oct 2024
General
01 Role of CD30 in hematolymphoid malignancies | Dr. Saeed Alshieban | 26 Oct 2024
Watched
General
2025
01 Role of CD30 in hematolymphoid malignancies | Dr. Saeed Alshieban | 26 Oct 2024
09 Castleman disease – updates | Dr. Ghaleb Elyamany | 26 Oct 2024
General
09 Castleman disease – updates | Dr. Ghaleb Elyamany | 26 Oct 2024
Watched
General
2025
09 Castleman disease – updates | Dr. Ghaleb Elyamany | 26 Oct 2024
08 EBV associated lymphoproliferative disorders | Dr. Shamayel Mohammed | 26 Oct 2024
General
08 EBV associated lymphoproliferative disorders | Dr. Shamayel Mohammed | 26 Oct 2024
Watched
General
2025
08 EBV associated lymphoproliferative disorders | Dr. Shamayel Mohammed | 26 Oct 2024
07 Pediatric lymphomas | Dr. Fadhel Alotaibi | 26 Oct 2024
General
07 Pediatric lymphomas | Dr. Fadhel Alotaibi | 26 Oct 2024
Watched
General
2025
07 Pediatric lymphomas | Dr. Fadhel Alotaibi | 26 Oct 2024
06 Gastrointestinal lymphomas | Dr. Leena Taher | 26 Oct 2024
General
06 Gastrointestinal lymphomas | Dr. Leena Taher | 26 Oct 2024
Watched
General
2025
06 Gastrointestinal lymphomas | Dr. Leena Taher | 26 Oct 2024
06 Mantel Cell Lymphoma in 2024: First line and relapsed disease treatment update | Dr. David Lewis
General
06 Mantel Cell Lymphoma in 2024: First line and relapsed disease treatment update | Dr. David Lewis
Watched
General
2025
06 Mantel Cell Lymphoma in 2024: First line and relapsed disease treatment update | Dr. David Lewis
05 Management of Multiple Myeloma Post-Auto Transplant | Dr. Hatem Al Ahwal | 25 Oct 2024
General
05 Management of Multiple Myeloma Post-Auto Transplant | Dr. Hatem Al Ahwal | 25 Oct 2024
Watched
General
2025
05 Management of Multiple Myeloma Post-Auto Transplant | Dr. Hatem Al Ahwal | 25 Oct 2024
04 LBCL Case Presentation | Dr. Riad Elfakih | 25 Oct 2024
General
04 LBCL Case Presentation | Dr. Riad Elfakih | 25 Oct 2024
Watched
General
2025
04 LBCL Case Presentation | Dr. Riad Elfakih | 25 Oct 2024
02.2 Management of Follicular Lymphoma beyond first line | Dr. Ihab Elhemaidi | 25 Oct 2024
General
02.2 Management of Follicular Lymphoma beyond first line | Dr. Ihab Elhemaidi | 25 Oct 2024
Watched
General
2025
02.2 Management of Follicular Lymphoma beyond first line | Dr. Ihab Elhemaidi | 25 Oct 2024
02 Management of Follicular Lymphoma beyond first line | Dr. Ihab Elhemaidi | 25 Oct 2024
General
02 Management of Follicular Lymphoma beyond first line | Dr. Ihab Elhemaidi | 25 Oct 2024
Watched
General
2025
02 Management of Follicular Lymphoma beyond first line | Dr. Ihab Elhemaidi | 25 Oct 2024
11 Updates on Burkitts lymphoma | Dr. Musa Alzahrani | 25 Oct 2024
General
11 Updates on Burkitts lymphoma | Dr. Musa Alzahrani | 25 Oct 2024
Watched
General
2025
11 Updates on Burkitts lymphoma | Dr. Musa Alzahrani | 25 Oct 2024
10 Bispecifics changing the treatment paradigm in R/R DLBCL | Dr. Martin Hutchings | 25 Oct 2024
General
10 Bispecifics changing the treatment paradigm in R/R DLBCL | Dr. Martin Hutchings | 25 Oct 2024
Watched
General
2025
10 Bispecifics changing the treatment paradigm in R/R DLBCL | Dr. Martin Hutchings | 25 Oct 2024
09 Refractory/Relapsed CLL | Dr. Mohammed Almakadi | 25 Oct 2024
General
09 Refractory/Relapsed CLL | Dr. Mohammed Almakadi | 25 Oct 2024
Watched
General
2025
09 Refractory/Relapsed CLL | Dr. Mohammed Almakadi | 25 Oct 2024
08 Bispecifics antibodies in Multiple Myeloma | Dr. Joshua Richter | 25 Oct 2025
General
08 Bispecifics antibodies in Multiple Myeloma | Dr. Joshua Richter | 25 Oct 2025
Watched
General
2025
08 Bispecifics antibodies in Multiple Myeloma | Dr. Joshua Richter | 25 Oct 2025
07 CLL and Richter transformation – Current thinking | Dr. Toby Eyre | 25 Oct 2024
General
07 CLL and Richter transformation – Current thinking | Dr. Toby Eyre | 25 Oct 2024
Watched
General
2025
07 CLL and Richter transformation – Current thinking | Dr. Toby Eyre | 25 Oct 2024
15 The evolving role of next generation BTK in Mantle Cell Lymphoma | Dr. Ihab Elhemaidi | 25Oct2024
General
15 The evolving role of next generation BTK in Mantle Cell Lymphoma | Dr. Ihab Elhemaidi | 25Oct2024
Watched
General
2025
15 The evolving role of next generation BTK in Mantle Cell Lymphoma | Dr. Ihab Elhemaidi | 25Oct2024
14 From Evidence to Practice: Role of Daratumumab in Shaping Currents& Future Mngt |Dr. Imran Tailor
General
14 From Evidence to Practice: Role of Daratumumab in Shaping Currents& Future Mngt |Dr. Imran Tailor
Watched
General
2025
14 From Evidence to Practice: Role of Daratumumab in Shaping Currents& Future Mngt |Dr. Imran Tailor
12 Peripheral T-Cell Lymphoma, incorporating novel therapies | Dr. Steven Horwitz | 25 Oct 2024
General
12 Peripheral T-Cell Lymphoma, incorporating novel therapies | Dr. Steven Horwitz | 25 Oct 2024
Watched
General
2025
12 Peripheral T-Cell Lymphoma, incorporating novel therapies | Dr. Steven Horwitz | 25 Oct 2024
13 Targeting Nuclear Export Proteins in Multiple Myeloma Therapy | Dr. Joshua Richter | 25 Oct 2024
General
13 Targeting Nuclear Export Proteins in Multiple Myeloma Therapy | Dr. Joshua Richter | 25 Oct 2024
Watched
General
2025
13 Targeting Nuclear Export Proteins in Multiple Myeloma Therapy | Dr. Joshua Richter | 25 Oct 2024
01 Hodgkin’s lymphoma frontline management in 2024 | Dr. Mubarak Almansour | 25 Oct 2024
General
01 Hodgkin’s lymphoma frontline management in 2024 | Dr. Mubarak Almansour | 25 Oct 2024
Watched
General
2025
01 Hodgkin’s lymphoma frontline management in 2024 | Dr. Mubarak Almansour | 25 Oct 2024
12. Mis-matched Unrelated Donors with PTCY | Dr. Heather Stefanski | May 10, 2025
General
12. Mis-matched Unrelated Donors with PTCY | Dr. Heather Stefanski | May 10, 2025
Watched
General
2025
12. Mis-matched Unrelated Donors with PTCY | Dr. Heather Stefanski | May 10, 2025
2. Conditioning regimen for HCT in TDT: review of available literature | Dr. Mohammed Essa | May 10
General
2. Conditioning regimen for HCT in TDT: review of available literature | Dr. Mohammed Essa | May 10
Watched
General
2025
2. Conditioning regimen for HCT in TDT: review of available literature | Dr. Mohammed Essa | May 10
1. Infections in CAR T patients | Dr. Lidia Gil | May 10,2025
General
1. Infections in CAR T patients | Dr. Lidia Gil | May 10,2025
Watched
General
2025
1. Infections in CAR T patients | Dr. Lidia Gil | May 10,2025
8. KFSH-Dammam Experience in Chronic GvHD | Dr. Zahrah Alshammasi | May 10, 2025
General
8. KFSH-Dammam Experience in Chronic GvHD | Dr. Zahrah Alshammasi | May 10, 2025
Watched
General
2025
8. KFSH-Dammam Experience in Chronic GvHD | Dr. Zahrah Alshammasi | May 10, 2025
7. CAR-T Cell Therapy Outcomes in Lymphoma: NGHA Jeddah Experience | Dr. Sameer Alamoudi | May 10
General
7. CAR-T Cell Therapy Outcomes in Lymphoma: NGHA Jeddah Experience | Dr. Sameer Alamoudi | May 10
Watched
General
2025
7. CAR-T Cell Therapy Outcomes in Lymphoma: NGHA Jeddah Experience | Dr. Sameer Alamoudi | May 10
6. Stem Cell Transplant for Multiple Sclerosis, Local Experience | Dr. Mohsen Alzahrani | May 10 '25
General
6. Stem Cell Transplant for Multiple Sclerosis, Local Experience | Dr. Mohsen Alzahrani | May 10 '25
Watched
General
2025
6. Stem Cell Transplant for Multiple Sclerosis, Local Experience | Dr. Mohsen Alzahrani | May 10 '25
5. Unlocking cure in the complement – Inhibitor Era | Dr. Wael Al Anazi | May 10, 2025
General
5. Unlocking cure in the complement – Inhibitor Era | Dr. Wael Al Anazi | May 10, 2025
Watched
General
2025
5. Unlocking cure in the complement – Inhibitor Era | Dr. Wael Al Anazi | May 10, 2025
4. CAR in autoimmune disease | Dr. Giorgio Orofino | May 10, 2025
General
4. CAR in autoimmune disease | Dr. Giorgio Orofino | May 10, 2025
Watched
General
2025
4. CAR in autoimmune disease | Dr. Giorgio Orofino | May 10, 2025
03. Identifying SCD & TDT patients for Advanced Therapy | Dr. Sameer Alamoudi | May 10, 2025
General
03. Identifying SCD & TDT patients for Advanced Therapy | Dr. Sameer Alamoudi | May 10, 2025
Watched
General
2025
03. Identifying SCD & TDT patients for Advanced Therapy | Dr. Sameer Alamoudi | May 10, 2025
11. The evolving field of Gene therapy for Hemoglobinopathies | Dr. Leslie Lehman | May 10, 2025
General
11. The evolving field of Gene therapy for Hemoglobinopathies | Dr. Leslie Lehman | May 10, 2025
Watched
General
2025
11. The evolving field of Gene therapy for Hemoglobinopathies | Dr. Leslie Lehman | May 10, 2025
10. Integrating MRD into AML Transplantation | Dr. Antonio Jimenez | May 10, 2025
General
10. Integrating MRD into AML Transplantation | Dr. Antonio Jimenez | May 10, 2025
Watched
General
2025
10. Integrating MRD into AML Transplantation | Dr. Antonio Jimenez | May 10, 2025
09. Anti-CD7 Allogeneic CAR-T Cell Therapy for the Treatment of T-cell Malignancies -Dr.Kabakibi
General
09. Anti-CD7 Allogeneic CAR-T Cell Therapy for the Treatment of T-cell Malignancies -Dr.Kabakibi
Watched
General
2025
09. Anti-CD7 Allogeneic CAR-T Cell Therapy for the Treatment of T-cell Malignancies -Dr.Kabakibi
11. Role of Blinatumomab in the frontline consolidation phase | Dr. Saleem Eldadah | May 9, 2025
General
11. Role of Blinatumomab in the frontline consolidation phase | Dr. Saleem Eldadah | May 9, 2025
Watched
General
2025
11. Role of Blinatumomab in the frontline consolidation phase | Dr. Saleem Eldadah | May 9, 2025
10. Timing of allo-HCT in Myelofibrosis: not too early, not too late | Dr. Nicola Polverelli | May 9
General
10. Timing of allo-HCT in Myelofibrosis: not too early, not too late | Dr. Nicola Polverelli | May 9
Watched
General
2025
10. Timing of allo-HCT in Myelofibrosis: not too early, not too late | Dr. Nicola Polverelli | May 9
09. Management of Ruxolitinib-refractory GVHD | Dr. Corey S. Cutler | May 9, 2025
General
09. Management of Ruxolitinib-refractory GVHD | Dr. Corey S. Cutler | May 9, 2025
Watched
General
2025
09. Management of Ruxolitinib-refractory GVHD | Dr. Corey S. Cutler | May 9, 2025
SSBMT WEBINAR SERIES - HOW I TREAT MDS?
Webinar
SSBMT WEBINAR SERIES - HOW I TREAT MDS?
Watched
Webinar
2025
SSBMT WEBINAR SERIES - HOW I TREAT MDS?
06. CAR-T cell Treatment Strategies in Patient with Lymphomas | Dr. Anna Sureda | May 9, 2025
General
06. CAR-T cell Treatment Strategies in Patient with Lymphomas | Dr. Anna Sureda | May 9, 2025
Watched
General
2025
06. CAR-T cell Treatment Strategies in Patient with Lymphomas | Dr. Anna Sureda | May 9, 2025
05. Anti HLA antibodies in HCT outcome | Dr. Annalisa Ruggeri | May 9, 2025
General
05. Anti HLA antibodies in HCT outcome | Dr. Annalisa Ruggeri | May 9, 2025
Watched
General
2025
05. Anti HLA antibodies in HCT outcome | Dr. Annalisa Ruggeri | May 9, 2025
04. Ex vivo graft engineering in allo-HCT | Dr. Florent Malard | May 9, 2025
General
04. Ex vivo graft engineering in allo-HCT | Dr. Florent Malard | May 9, 2025
Watched
General
2025
04. Ex vivo graft engineering in allo-HCT | Dr. Florent Malard | May 9, 2025
03. Immunotherapy and beyond in multiple myeloma | Dr. Omar Abduljalil | May 9, 2025
General
03. Immunotherapy and beyond in multiple myeloma | Dr. Omar Abduljalil | May 9, 2025
Watched
General
2025
03. Immunotherapy and beyond in multiple myeloma | Dr. Omar Abduljalil | May 9, 2025
02. Management of Relapsed B-ALL in the Post CAR-T Setting | Dr. Valentin Ortiz | May 9, 2025
General
02. Management of Relapsed B-ALL in the Post CAR-T Setting | Dr. Valentin Ortiz | May 9, 2025
Watched
General
2025
02. Management of Relapsed B-ALL in the Post CAR-T Setting | Dr. Valentin Ortiz | May 9, 2025
01. The Role of CART Therapy and Bi-specific Antibodies | Dr. Cristof Scheid | May 09, 2025
General
01. The Role of CART Therapy and Bi-specific Antibodies | Dr. Cristof Scheid | May 09, 2025
Watched
General
2025
01. The Role of CART Therapy and Bi-specific Antibodies | Dr. Cristof Scheid | May 09, 2025
08. New Era in Hemoglobinopathies Management | Dr. Fahad Al Manjomi | May 9, 2025
General
08. New Era in Hemoglobinopathies Management | Dr. Fahad Al Manjomi | May 9, 2025
Watched
General
2025
08. New Era in Hemoglobinopathies Management | Dr. Fahad Al Manjomi | May 9, 2025
07.Defining theTreatment Trajectory in Transplant-eligible Saudi MyelomaPopulation-Dr.OmarAbduljalil
General
07.Defining theTreatment Trajectory in Transplant-eligible Saudi MyelomaPopulation-Dr.OmarAbduljalil
Watched
General
2025
07.Defining theTreatment Trajectory in Transplant-eligible Saudi MyelomaPopulation-Dr.OmarAbduljalil
SSBMT
General
SSBMT
Watched
General
2025
SSBMT
SSH & SSBMT Combined Annual Conference 11-12 April 2025
General
SSH & SSBMT Combined Annual Conference 11-12 April 2025
Watched
General
2025
SSH & SSBMT Combined Annual Conference 11-12 April 2025
SSH & SSBMT Combined Annal Conference 11-12 April 2025
General
SSH & SSBMT Combined Annal Conference 11-12 April 2025
Watched
General
2025
SSH & SSBMT Combined Annal Conference 11-12 April 2025
SSBMT & SSCDR participation at the Tandem Meetings of ASTCT & CIBMTR 2025 , Hawaii Convention Center
General
SSBMT & SSCDR participation at the Tandem Meetings of ASTCT & CIBMTR 2025 , Hawaii Convention Center
Watched
General
2025
SSBMT & SSCDR participation at the Tandem Meetings of ASTCT & CIBMTR 2025 , Hawaii Convention Center
SSBMT & SSCDR participation at the Tandem Meetings of ASTCT & CIBMTR 2025 , Hawaii Convention Center
General
SSBMT & SSCDR participation at the Tandem Meetings of ASTCT & CIBMTR 2025 , Hawaii Convention Center
Watched
General
2025
SSBMT & SSCDR participation at the Tandem Meetings of ASTCT & CIBMTR 2025 , Hawaii Convention Center
SSBMT Webinar Series - Revolutionizing LR-MDS Treatment: The Next Generation of Care
Webinar
SSBMT Webinar Series - Revolutionizing LR-MDS Treatment: The Next Generation of Care
Watched
Webinar
2024
SSBMT Webinar Series - Revolutionizing LR-MDS Treatment: The Next Generation of Care
Saudi Lyphoma/Myeloma & Hematopathology Overview 2024 (Oct 26, 2024) Le Meridien Medina Hotel
General
Saudi Lyphoma/Myeloma & Hematopathology Overview 2024 (Oct 26, 2024) Le Meridien Medina Hotel
Watched
General
2024
Saudi Lyphoma/Myeloma & Hematopathology Overview 2024 (Oct 26, 2024) Le Meridien Medina Hotel
Saudi Lymphoma/Myeloma & Hematopathology Overview 2024 (OCt 25-26, 2024) Le Meridien Medina Hotel
General
Saudi Lymphoma/Myeloma & Hematopathology Overview 2024 (OCt 25-26, 2024) Le Meridien Medina Hotel
Watched
General
2024
Saudi Lymphoma/Myeloma & Hematopathology Overview 2024 (OCt 25-26, 2024) Le Meridien Medina Hotel
Saudi Lyphoma/Myeloma & Hematopathology Overview 2024 (Oct 25-26, 2024) Le Meridien Medina Hotel
General
Saudi Lyphoma/Myeloma & Hematopathology Overview 2024 (Oct 25-26, 2024) Le Meridien Medina Hotel
Watched
General
2024
Saudi Lyphoma/Myeloma & Hematopathology Overview 2024 (Oct 25-26, 2024) Le Meridien Medina Hotel
13th Annual SSBMT Conference
General
13th Annual SSBMT Conference
Watched
General
2024
13th Annual SSBMT Conference
13th Annual SSBMT Conference
General
13th Annual SSBMT Conference
Watched
General
2024
13th Annual SSBMT Conference
DLBCL – How to best sequence immunotherapies | Dr. John Apostolidis (16 Feb 2024)
General
DLBCL – How to best sequence immunotherapies | Dr. John Apostolidis (16 Feb 2024)
Watched
General
2024
DLBCL – How to best sequence immunotherapies | Dr. John Apostolidis (16 Feb 2024)
High prevalence of a rare bleeding disorder in Al-Madinah | Dr. Ahmad Tarawah (16 Feb 2024)
General
High prevalence of a rare bleeding disorder in Al-Madinah | Dr. Ahmad Tarawah (16 Feb 2024)
Watched
General
2024
High prevalence of a rare bleeding disorder in Al-Madinah | Dr. Ahmad Tarawah (16 Feb 2024)
Difficult Bleeding consultations in the Hospital | Dr. Mervat Mattar (16 Feb 2024)
General
Difficult Bleeding consultations in the Hospital | Dr. Mervat Mattar (16 Feb 2024)
Watched
General
2024
Difficult Bleeding consultations in the Hospital | Dr. Mervat Mattar (16 Feb 2024)
Familial Thrombophilia screening | Dr. Tarek Owaidah (16 February 2024)
General
Familial Thrombophilia screening | Dr. Tarek Owaidah (16 February 2024)
Watched
General
2024
Familial Thrombophilia screening | Dr. Tarek Owaidah (16 February 2024)
Integrated information systems to support patient care and research | Dr. Scott Howard (16 Feb 2024)
General
Integrated information systems to support patient care and research | Dr. Scott Howard (16 Feb 2024)
Watched
General
2024
Integrated information systems to support patient care and research | Dr. Scott Howard (16 Feb 2024)
ALL–How novel agents are improving outcomes and decreasing toxicity|Dr. Murtada Khabouri(16 Feb2024)
General
ALL–How novel agents are improving outcomes and decreasing toxicity|Dr. Murtada Khabouri(16 Feb2024)
Watched
General
2024
ALL–How novel agents are improving outcomes and decreasing toxicity|Dr. Murtada Khabouri(16 Feb2024)
Mantle Cell – Where we stand in 2024 | Dr. Reyad Dada (16 Feb 2024)
General
Mantle Cell – Where we stand in 2024 | Dr. Reyad Dada (16 Feb 2024)
Watched
General
2024
Mantle Cell – Where we stand in 2024 | Dr. Reyad Dada (16 Feb 2024)
What is the best first-line therapy for Hodgkin Lymphoma | Dr. Pier Luigi Zinzani (16 Feb 2024)
General
What is the best first-line therapy for Hodgkin Lymphoma | Dr. Pier Luigi Zinzani (16 Feb 2024)
Watched
General
2024
What is the best first-line therapy for Hodgkin Lymphoma | Dr. Pier Luigi Zinzani (16 Feb 2024)
Beta-thalassemia What is New | Dr. Abdullah Al Zayed (16 Feb 2024)
General
Beta-thalassemia What is New | Dr. Abdullah Al Zayed (16 Feb 2024)
Watched
General
2024
Beta-thalassemia What is New | Dr. Abdullah Al Zayed (16 Feb 2024)
Sickle Cell Disease – Current therapeutic options | Dr. Sultan Al Mutairi (16 Feb 2024)
General
Sickle Cell Disease – Current therapeutic options | Dr. Sultan Al Mutairi (16 Feb 2024)
Watched
General
2024
Sickle Cell Disease – Current therapeutic options | Dr. Sultan Al Mutairi (16 Feb 2024)
Beyond Malignancy: Hematological Manifestations of Gaucher & ASMD | Dr. Mohamed Nabulsi(16 Feb 2024)
General
Beyond Malignancy: Hematological Manifestations of Gaucher & ASMD | Dr. Mohamed Nabulsi(16 Feb 2024)
Watched
General
2024
Beyond Malignancy: Hematological Manifestations of Gaucher & ASMD | Dr. Mohamed Nabulsi(16 Feb 2024)
CML updates |Dr. Murtada Khabouri (16 Feb 2024)
General
CML updates |Dr. Murtada Khabouri (16 Feb 2024)
Watched
General
2024
CML updates |Dr. Murtada Khabouri (16 Feb 2024)
CML management updates beyond second TKI | Dr. Ihab Elhemaidi (17 Feb 2024)
General
CML management updates beyond second TKI | Dr. Ihab Elhemaidi (17 Feb 2024)
Watched
General
2024
CML management updates beyond second TKI | Dr. Ihab Elhemaidi (17 Feb 2024)
BCMA – Targeted Therapies in MM | Dr. Ghazi Alotaibi (16 Feb 2024)
General
BCMA – Targeted Therapies in MM | Dr. Ghazi Alotaibi (16 Feb 2024)
Watched
General
2024
BCMA – Targeted Therapies in MM | Dr. Ghazi Alotaibi (16 Feb 2024)
Bispecifics for Multiple Myeloma | Dr. Ayman Alhejazi (16 Feb 2024)
General
Bispecifics for Multiple Myeloma | Dr. Ayman Alhejazi (16 Feb 2024)
Watched
General
2024
Bispecifics for Multiple Myeloma | Dr. Ayman Alhejazi (16 Feb 2024)
Late Complications of Chronic GVHD | Dr. Zinaida Peric (16 Feb 2024)
General
Late Complications of Chronic GVHD | Dr. Zinaida Peric (16 Feb 2024)
Watched
General
2024
Late Complications of Chronic GVHD | Dr. Zinaida Peric (16 Feb 2024)
Gene Therapy: New Era in Haemoglobinopathies | Dr. Josu de la Fuente (16 Feb 2024)
General
Gene Therapy: New Era in Haemoglobinopathies | Dr. Josu de la Fuente (16 Feb 2024)
Watched
General
2024
Gene Therapy: New Era in Haemoglobinopathies | Dr. Josu de la Fuente (16 Feb 2024)
Comparison of a modified pediatric protocol vs hyper-CVAD protocol | Dr. Hind Salama (17 Feb 2024)
General
Comparison of a modified pediatric protocol vs hyper-CVAD protocol | Dr. Hind Salama (17 Feb 2024)
Watched
General
2024
Comparison of a modified pediatric protocol vs hyper-CVAD protocol | Dr. Hind Salama (17 Feb 2024)
Favorable fertility outcome in a large cohort of sickle cell disease-Dr. Mazin Abdulsalam(17Feb2024)
General
Favorable fertility outcome in a large cohort of sickle cell disease-Dr. Mazin Abdulsalam(17Feb2024)
Watched
General
2024
Favorable fertility outcome in a large cohort of sickle cell disease-Dr. Mazin Abdulsalam(17Feb2024)
Bispecific in Myeloma | Dr. Ahmed Al Huraiji (17 Feb 2024)
General
Bispecific in Myeloma | Dr. Ahmed Al Huraiji (17 Feb 2024)
Watched
General
2024
Bispecific in Myeloma | Dr. Ahmed Al Huraiji (17 Feb 2024)
Treatment of c-GVHD – Updates | Dr. Monzr Al Malki (17 Feb 2024)
General
Treatment of c-GVHD – Updates | Dr. Monzr Al Malki (17 Feb 2024)
Watched
General
2024
Treatment of c-GVHD – Updates | Dr. Monzr Al Malki (17 Feb 2024)
CAR-T Role in ALL – A true game changer or otherwise | Dr. Mohsen Alzahrani (17 Feb 2024)
General
CAR-T Role in ALL – A true game changer or otherwise | Dr. Mohsen Alzahrani (17 Feb 2024)
Watched
General
2024
CAR-T Role in ALL – A true game changer or otherwise | Dr. Mohsen Alzahrani (17 Feb 2024)
CAR-T in Myeloma | Dr. Sameer Al Amoudi (17 Feb 2024)
General
CAR-T in Myeloma | Dr. Sameer Al Amoudi (17 Feb 2024)
Watched
General
2024
CAR-T in Myeloma | Dr. Sameer Al Amoudi (17 Feb 2024)
New Anticoagulation Guidelines – Update | Dr. Ashraf Warsi (17 Feb 2024)
General
New Anticoagulation Guidelines – Update | Dr. Ashraf Warsi (17 Feb 2024)
Watched
General
2024
New Anticoagulation Guidelines – Update | Dr. Ashraf Warsi (17 Feb 2024)
Anticoagulation beyond DOACS | Dr. Hanan Hamed (17 Feb 2024)
General
Anticoagulation beyond DOACS | Dr. Hanan Hamed (17 Feb 2024)
Watched
General
2024
Anticoagulation beyond DOACS | Dr. Hanan Hamed (17 Feb 2024)
CLL – Upfront therapy – practical decisions – Dr. Khalid Halahleh (17 Feb 2024)
General
CLL – Upfront therapy – practical decisions – Dr. Khalid Halahleh (17 Feb 2024)
Watched
General
2024
CLL – Upfront therapy – practical decisions – Dr. Khalid Halahleh (17 Feb 2024)
Advances in AL Amyloidosis | Dr. Majed Al Ahmadi (17 Feb 2024)
General
Advances in AL Amyloidosis | Dr. Majed Al Ahmadi (17 Feb 2024)
Watched
General
2024
Advances in AL Amyloidosis | Dr. Majed Al Ahmadi (17 Feb 2024)
Incorporating Palliative care in Hematology patients | Dr. Nabil Almouaalamy (17 Feb 2024)
General
Incorporating Palliative care in Hematology patients | Dr. Nabil Almouaalamy (17 Feb 2024)
Watched
General
2024
Incorporating Palliative care in Hematology patients | Dr. Nabil Almouaalamy (17 Feb 2024)
Role of Artificial Intelligence in Hematology and the Future of Medicine | Dr. Aziz Nazha(17Feb2024)
General
Role of Artificial Intelligence in Hematology and the Future of Medicine | Dr. Aziz Nazha(17Feb2024)
Watched
General
2024
Role of Artificial Intelligence in Hematology and the Future of Medicine | Dr. Aziz Nazha(17Feb2024)
New Therapeutic Approaches for Lower-Risk Myelodysplastic Syndromes | Dr. Bader Alahmari (17Feb2024)
General
New Therapeutic Approaches for Lower-Risk Myelodysplastic Syndromes | Dr. Bader Alahmari (17Feb2024)
Watched
General
2024
New Therapeutic Approaches for Lower-Risk Myelodysplastic Syndromes | Dr. Bader Alahmari (17Feb2024)
Validation of long term handling & storage condition | Dr. Ahmed Al Bahrani (17 Feb 2024)
General
Validation of long term handling & storage condition | Dr. Ahmed Al Bahrani (17 Feb 2024)
Watched
General
2024
Validation of long term handling & storage condition | Dr. Ahmed Al Bahrani (17 Feb 2024)
Hemophilia – Very exciting developments | Dr. Eman Mansory (17 Feb 2024)
General
Hemophilia – Very exciting developments | Dr. Eman Mansory (17 Feb 2024)
Watched
General
2024
Hemophilia – Very exciting developments | Dr. Eman Mansory (17 Feb 2024)
Optimal Management of CNS ALL and harnessing HDMTX toxicity | Dr. Scott Howard (16 Feb 2024)
General
Optimal Management of CNS ALL and harnessing HDMTX toxicity | Dr. Scott Howard (16 Feb 2024)
Watched
General
2024
Optimal Management of CNS ALL and harnessing HDMTX toxicity | Dr. Scott Howard (16 Feb 2024)
AML–Improving outcomes w incorporation of Novel agents | Dr. Monzr M. Al Malki (16 Feb 2024)
General
AML–Improving outcomes w incorporation of Novel agents | Dr. Monzr M. Al Malki (16 Feb 2024)
Watched
General
2024
AML–Improving outcomes w incorporation of Novel agents | Dr. Monzr M. Al Malki (16 Feb 2024)
SSBMT Webinar Series - “MDS New Therapeutic Approaches“
Webinar
SSBMT Webinar Series - “MDS New Therapeutic Approaches“
Watched
Webinar
2024
SSBMT Webinar Series - “MDS New Therapeutic Approaches“
MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS – Dr. John Apostolidis (Sept 15-16, 2023)
General
MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS – Dr. John Apostolidis (Sept 15-16, 2023)
Watched
General
2024
MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS – Dr. John Apostolidis (Sept 15-16, 2023)
Multiple myeloma, recent advances – Dr. Ayman Alhejazi (September 15-16, 2023)
General
Multiple myeloma, recent advances – Dr. Ayman Alhejazi (September 15-16, 2023)
Watched
General
2024
Multiple myeloma, recent advances – Dr. Ayman Alhejazi (September 15-16, 2023)
ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS – Dr. Davide Rossi (Sep 15-16, 2023)
General
ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS – Dr. Davide Rossi (Sep 15-16, 2023)
Watched
General
2024
ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS – Dr. Davide Rossi (Sep 15-16, 2023)
IBRUTINIB VERSUS PLACEBO IN PTS. W/ ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CLL–Dr. Davide Rossi
General
IBRUTINIB VERSUS PLACEBO IN PTS. W/ ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CLL–Dr. Davide Rossi
Watched
General
2024
IBRUTINIB VERSUS PLACEBO IN PTS. W/ ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CLL–Dr. Davide Rossi
Splenic B cell lymphoma/leukemia – Dr. Khalid Alayed (September 15-16, 2023)
General
Splenic B cell lymphoma/leukemia – Dr. Khalid Alayed (September 15-16, 2023)
Watched
General
2024
Splenic B cell lymphoma/leukemia – Dr. Khalid Alayed (September 15-16, 2023)
Plasma cell neoplasms (IMWG update) – Dr. Ahmed Alrajjal (September 15-16, 2023)
General
Plasma cell neoplasms (IMWG update) – Dr. Ahmed Alrajjal (September 15-16, 2023)
Watched
General
2024
Plasma cell neoplasms (IMWG update) – Dr. Ahmed Alrajjal (September 15-16, 2023)
Challenging cases (Myeloid neoplasms) – Dr. Heba Raslan (September 15-16, 2023)
General
Challenging cases (Myeloid neoplasms) – Dr. Heba Raslan (September 15-16, 2023)
Watched
General
2024
Challenging cases (Myeloid neoplasms) – Dr. Heba Raslan (September 15-16, 2023)
Blastic plasmactoid dendritic cell neoplasm (BPDNC):An Overview –Dr. Ghaleb Elyamany(Sep15-16, 2023)
General
Blastic plasmactoid dendritic cell neoplasm (BPDNC):An Overview –Dr. Ghaleb Elyamany(Sep15-16, 2023)
Watched
General
2024
Blastic plasmactoid dendritic cell neoplasm (BPDNC):An Overview –Dr. Ghaleb Elyamany(Sep15-16, 2023)
Acute leukemia of ambiguous lineage – Dr. Areej Almoghairi (September 15-16, 2023)
General
Acute leukemia of ambiguous lineage – Dr. Areej Almoghairi (September 15-16, 2023)
Watched
General
2024
Acute leukemia of ambiguous lineage – Dr. Areej Almoghairi (September 15-16, 2023)
WHO updates in MDS and MPN – Dr. Nahlah AlGhasham (September 15-16, 2023)
General
WHO updates in MDS and MPN – Dr. Nahlah AlGhasham (September 15-16, 2023)
Watched
General
2024
WHO updates in MDS and MPN – Dr. Nahlah AlGhasham (September 15-16, 2023)
How to manage relapsed CLL and Richter’s transformation – Dr. Davide Rossi (September 15-16, 2023)
General
How to manage relapsed CLL and Richter’s transformation – Dr. Davide Rossi (September 15-16, 2023)
Watched
General
2024
How to manage relapsed CLL and Richter’s transformation – Dr. Davide Rossi (September 15-16, 2023)
PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA – Dr. Wael Alanazi
General
PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA – Dr. Wael Alanazi
Watched
General
2024
PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA – Dr. Wael Alanazi
An update on respiratory transfusion reactions – Dr. Maha Badawi (September 15-16, 2023)
General
An update on respiratory transfusion reactions – Dr. Maha Badawi (September 15-16, 2023)
Watched
General
2024
An update on respiratory transfusion reactions – Dr. Maha Badawi (September 15-16, 2023)
Challenging cases: Coagulation – Dr. Reem AlRabeh (September 15-16, 2023)
General
Challenging cases: Coagulation – Dr. Reem AlRabeh (September 15-16, 2023)
Watched
General
2024
Challenging cases: Coagulation – Dr. Reem AlRabeh (September 15-16, 2023)
Von Willebrand Disease (VWD) – Dr. Rahaf AlTahan (September 15-16, 2023)
General
Von Willebrand Disease (VWD) – Dr. Rahaf AlTahan (September 15-16, 2023)
Watched
General
2024
Von Willebrand Disease (VWD) – Dr. Rahaf AlTahan (September 15-16, 2023)
Challenging cases (Molecular hematology) – Dr. Abdullah AlSuwaidan (September 15-16, 2023)
General
Challenging cases (Molecular hematology) – Dr. Abdullah AlSuwaidan (September 15-16, 2023)
Watched
General
2024
Challenging cases (Molecular hematology) – Dr. Abdullah AlSuwaidan (September 15-16, 2023)
Advances in Hematology Molecular Diagnostics – Dr. Saeed Al Turki (September 15-16, 2023)
General
Advances in Hematology Molecular Diagnostics – Dr. Saeed Al Turki (September 15-16, 2023)
Watched
General
2024
Advances in Hematology Molecular Diagnostics – Dr. Saeed Al Turki (September 15-16, 2023)
Challenging cases (myeloma/lymphoma) – Dr. Reem AlRabeh (September 15-16, 2023)
General
Challenging cases (myeloma/lymphoma) – Dr. Reem AlRabeh (September 15-16, 2023)
Watched
General
2024
Challenging cases (myeloma/lymphoma) – Dr. Reem AlRabeh (September 15-16, 2023)
Hemophagocytic Lymphohistiocytosis (HLH) – Dr. Maher Aljhohani (September 15-16, 2023)
General
Hemophagocytic Lymphohistiocytosis (HLH) – Dr. Maher Aljhohani (September 15-16, 2023)
Watched
General
2024
Hemophagocytic Lymphohistiocytosis (HLH) – Dr. Maher Aljhohani (September 15-16, 2023)
Issues in neonatal/pediatric transfusion – Dr. Mukhtar Buhlaiga (September 15-16, 2023)
General
Issues in neonatal/pediatric transfusion – Dr. Mukhtar Buhlaiga (September 15-16, 2023)
Watched
General
2024
Issues in neonatal/pediatric transfusion – Dr. Mukhtar Buhlaiga (September 15-16, 2023)
Platelet refractoriness – Dr. Ammar Alsughayir (September 15-16, 2023)
General
Platelet refractoriness – Dr. Ammar Alsughayir (September 15-16, 2023)
Watched
General
2024
Platelet refractoriness – Dr. Ammar Alsughayir (September 15-16, 2023)
Where we are now and what’s the future for 1L DLBCL management – Dr. Ahmed Absi (Sep 15-16, 2023)
General
Where we are now and what’s the future for 1L DLBCL management – Dr. Ahmed Absi (Sep 15-16, 2023)
Watched
General
2024
Where we are now and what’s the future for 1L DLBCL management – Dr. Ahmed Absi (Sep 15-16, 2023)
Where we are now and what’s the future for 1L DLBCL management – Dr. Saleem Eldadah (Sep15-16, 2023)
General
Where we are now and what’s the future for 1L DLBCL management – Dr. Saleem Eldadah (Sep15-16, 2023)
Watched
General
2024
Where we are now and what’s the future for 1L DLBCL management – Dr. Saleem Eldadah (Sep15-16, 2023)
PHASE 2 STUDY OF IBRUTINIB WITH TEMOZOLOMIDE, ETOPOSIDE, LIPOSOMAL DOXORUBICIN, DEXAMETHASONE...
General
PHASE 2 STUDY OF IBRUTINIB WITH TEMOZOLOMIDE, ETOPOSIDE, LIPOSOMAL DOXORUBICIN, DEXAMETHASONE...
Watched
General
2024
PHASE 2 STUDY OF IBRUTINIB WITH TEMOZOLOMIDE, ETOPOSIDE, LIPOSOMAL DOXORUBICIN, DEXAMETHASONE...
CONSOLIDATIVE HCT-ASCT IS SUPERIOR TO NON-MYELOABLATIVE CHEMO-IMMUNOTHERAPY IN NEWLYDIAGNOSED PCNSL
General
CONSOLIDATIVE HCT-ASCT IS SUPERIOR TO NON-MYELOABLATIVE CHEMO-IMMUNOTHERAPY IN NEWLYDIAGNOSED PCNSL
Watched
General
2024
CONSOLIDATIVE HCT-ASCT IS SUPERIOR TO NON-MYELOABLATIVE CHEMO-IMMUNOTHERAPY IN NEWLYDIAGNOSED PCNSL
How to Improve the Efficacy of the Treatment Against PTCL – Dr. Andres Ferreri (Sept. 15-16, 2023)
General
How to Improve the Efficacy of the Treatment Against PTCL – Dr. Andres Ferreri (Sept. 15-16, 2023)
Watched
General
2024
How to Improve the Efficacy of the Treatment Against PTCL – Dr. Andres Ferreri (Sept. 15-16, 2023)
PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA 7 STUDY-Dr. Majed Alahmadi
General
PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA 7 STUDY-Dr. Majed Alahmadi
Watched
General
2024
PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA 7 STUDY-Dr. Majed Alahmadi
A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA PTS
General
A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA PTS
Watched
General
2024
A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA PTS
GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE
General
GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE
Watched
General
2024
GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE
Novel Agents in Relapsed/Refractory Diffuse Large B-Cell Lymphoma–Dr. Stefano Luminari(Sep15-16'23)
General
Novel Agents in Relapsed/Refractory Diffuse Large B-Cell Lymphoma–Dr. Stefano Luminari(Sep15-16'23)
Watched
General
2024
Novel Agents in Relapsed/Refractory Diffuse Large B-Cell Lymphoma–Dr. Stefano Luminari(Sep15-16'23)
NIVOLUMAB(N)-AVD IMPROVES PROGRESSION-FREE SURVIVAL – Dr. Gaetano Corazzelli (Sept 15-16, 2023)
General
NIVOLUMAB(N)-AVD IMPROVES PROGRESSION-FREE SURVIVAL – Dr. Gaetano Corazzelli (Sept 15-16, 2023)
Watched
General
2024
NIVOLUMAB(N)-AVD IMPROVES PROGRESSION-FREE SURVIVAL – Dr. Gaetano Corazzelli (Sept 15-16, 2023)
Advanced Hodgkin’s Lymphoma, new combinations using check point inhibitors– Dr. Gaetano Corazzelli
General
Advanced Hodgkin’s Lymphoma, new combinations using check point inhibitors– Dr. Gaetano Corazzelli
Watched
General
2024
Advanced Hodgkin’s Lymphoma, new combinations using check point inhibitors– Dr. Gaetano Corazzelli
BRECADD IS NON-INFERIOR TO EBEACOPP IN PATIENTS – Dr. Saleem Eldadah (Sept 15-16, 2023)
General
BRECADD IS NON-INFERIOR TO EBEACOPP IN PATIENTS – Dr. Saleem Eldadah (Sept 15-16, 2023)
Watched
General
2024
BRECADD IS NON-INFERIOR TO EBEACOPP IN PATIENTS – Dr. Saleem Eldadah (Sept 15-16, 2023)
Unravelling the Role of CCR4 as a therapeutic target in CTCL –Dr. John Apostolidis(Sep 15-16, 2023)
General
Unravelling the Role of CCR4 as a therapeutic target in CTCL –Dr. John Apostolidis(Sep 15-16, 2023)
Watched
General
2024
Unravelling the Role of CCR4 as a therapeutic target in CTCL –Dr. John Apostolidis(Sep 15-16, 2023)
Aggressive Lymphomas – Dr. Mathias Rummel (September 15-16, 2023)
General
Aggressive Lymphomas – Dr. Mathias Rummel (September 15-16, 2023)
Watched
General
2024
Aggressive Lymphomas – Dr. Mathias Rummel (September 15-16, 2023)
Advances in the Diagnosis and Treatment of BPDCN – Dr. Naveen Pemmaraju (May 26-27, 2023)
General
Advances in the Diagnosis and Treatment of BPDCN – Dr. Naveen Pemmaraju (May 26-27, 2023)
Watched
General
2024
Advances in the Diagnosis and Treatment of BPDCN – Dr. Naveen Pemmaraju (May 26-27, 2023)
Updates in CML Management – Dr. Jorge Cortes (May 26-27, 2023)
General
Updates in CML Management – Dr. Jorge Cortes (May 26-27, 2023)
Watched
General
2024
Updates in CML Management – Dr. Jorge Cortes (May 26-27, 2023)
Cord Blood Transplantation: Now and Next – Dr. Annalisa Ruggeri (May 26-27, 2023)
General
Cord Blood Transplantation: Now and Next – Dr. Annalisa Ruggeri (May 26-27, 2023)
Watched
General
2024
Cord Blood Transplantation: Now and Next – Dr. Annalisa Ruggeri (May 26-27, 2023)
Cellular Therapy in Lymphomas – Dr. Anna Sureda (May 26-27, 2023)
General
Cellular Therapy in Lymphomas – Dr. Anna Sureda (May 26-27, 2023)
Watched
General
2024
Cellular Therapy in Lymphomas – Dr. Anna Sureda (May 26-27, 2023)
Frontline Intensified Abvd Demonstrates Superior Efficacy –Dr. Gaetano Corazzelli (Sept 15-16, 2023)
General
Frontline Intensified Abvd Demonstrates Superior Efficacy –Dr. Gaetano Corazzelli (Sept 15-16, 2023)
Watched
General
2024
Frontline Intensified Abvd Demonstrates Superior Efficacy –Dr. Gaetano Corazzelli (Sept 15-16, 2023)
CAR T-Cell Therapy – Pediatric Local Experience – Dr. Ali Abdallah Al Ahmari (May 26-27, 2023)
General
CAR T-Cell Therapy – Pediatric Local Experience – Dr. Ali Abdallah Al Ahmari (May 26-27, 2023)
Watched
General
2024
CAR T-Cell Therapy – Pediatric Local Experience – Dr. Ali Abdallah Al Ahmari (May 26-27, 2023)
CAR T-Cell Therapy – Adult Local Experience – Dr. Ali Debsan Al Ahmari (May 26-27, 2023)
General
CAR T-Cell Therapy – Adult Local Experience – Dr. Ali Debsan Al Ahmari (May 26-27, 2023)
Watched
General
2024
CAR T-Cell Therapy – Adult Local Experience – Dr. Ali Debsan Al Ahmari (May 26-27, 2023)
Steroid-Refractory Chronic GVHD – Dr. Zinaida Peric (May 26-27, 2023)
General
Steroid-Refractory Chronic GVHD – Dr. Zinaida Peric (May 26-27, 2023)
Watched
General
2024
Steroid-Refractory Chronic GVHD – Dr. Zinaida Peric (May 26-27, 2023)
Management of Immuno-Toxicity in Patients Receiving CAR T-Cell Therapy– Dr.ClaireRoddie(May26-27'23)
General
Management of Immuno-Toxicity in Patients Receiving CAR T-Cell Therapy– Dr.ClaireRoddie(May26-27'23)
Watched
General
2024
Management of Immuno-Toxicity in Patients Receiving CAR T-Cell Therapy– Dr.ClaireRoddie(May26-27'23)
Gene Therapy in Hemoglobinopathies – Dr. Emanuele Angelucci (May 26-27, 2023)
General
Gene Therapy in Hemoglobinopathies – Dr. Emanuele Angelucci (May 26-27, 2023)
Watched
General
2024
Gene Therapy in Hemoglobinopathies – Dr. Emanuele Angelucci (May 26-27, 2023)
Haplo donors vs MUD in High risk AML – Dr. Didier Blaise (May 26-27, 2023)
General
Haplo donors vs MUD in High risk AML – Dr. Didier Blaise (May 26-27, 2023)
Watched
General
2024
Haplo donors vs MUD in High risk AML – Dr. Didier Blaise (May 26-27, 2023)
Management of AML in Adults: Consensus of the SSBMT – Dr. Bader Al Ahmari (May 26-27, 2023)
General
Management of AML in Adults: Consensus of the SSBMT – Dr. Bader Al Ahmari (May 26-27, 2023)
Watched
General
2024
Management of AML in Adults: Consensus of the SSBMT – Dr. Bader Al Ahmari (May 26-27, 2023)
Chimeric Antigen Receptor T-Cell Therapy for B-Cell Malignancies–Dr. Bader Al Ahmari(May26-27,2023)
General
Chimeric Antigen Receptor T-Cell Therapy for B-Cell Malignancies–Dr. Bader Al Ahmari(May26-27,2023)
Watched
General
2024
Chimeric Antigen Receptor T-Cell Therapy for B-Cell Malignancies–Dr. Bader Al Ahmari(May26-27,2023)
AML: The Art of Remission Maintenance – Dr. Charles Craddock (May 26-27, 2023)
General
AML: The Art of Remission Maintenance – Dr. Charles Craddock (May 26-27, 2023)
Watched
General
2024
AML: The Art of Remission Maintenance – Dr. Charles Craddock (May 26-27, 2023)
Management of Relapsed Refractory AML with FLT3 +ve mutation – Dr. Ahmad Alotaibi (May 26-27, 2023)
General
Management of Relapsed Refractory AML with FLT3 +ve mutation – Dr. Ahmad Alotaibi (May 26-27, 2023)
Watched
General
2024
Management of Relapsed Refractory AML with FLT3 +ve mutation – Dr. Ahmad Alotaibi (May 26-27, 2023)
Challenges &Opportunities in RRMM Management and role of Isatuximab–Dr.Joshua Richter(May26-27,2023)
General
Challenges &Opportunities in RRMM Management and role of Isatuximab–Dr.Joshua Richter(May26-27,2023)
Watched
General
2024
Challenges &Opportunities in RRMM Management and role of Isatuximab–Dr.Joshua Richter(May26-27,2023)
Wondering Hepatosplenomegaly? Not Always a Malignancy – Dr. Maha Faden (May 26-27, 2023)
General
Wondering Hepatosplenomegaly? Not Always a Malignancy – Dr. Maha Faden (May 26-27, 2023)
Watched
General
2024
Wondering Hepatosplenomegaly? Not Always a Malignancy – Dr. Maha Faden (May 26-27, 2023)
Thalassemia: Advances in SCT & Gene Therapy – Dr. Josu de la Fuente (May 26-27, 2023)
General
Thalassemia: Advances in SCT & Gene Therapy – Dr. Josu de la Fuente (May 26-27, 2023)
Watched
General
2024
Thalassemia: Advances in SCT & Gene Therapy – Dr. Josu de la Fuente (May 26-27, 2023)
Cellular therapy in Multiple Myeloma – Dr. Paula Rodríguez de Otero (May 26-27, 2023)
General
Cellular therapy in Multiple Myeloma – Dr. Paula Rodríguez de Otero (May 26-27, 2023)
Watched
General
2024
Cellular therapy in Multiple Myeloma – Dr. Paula Rodríguez de Otero (May 26-27, 2023)
Stem Cell Transplant for SCD – Dr. Mohsen Alzahrani (May 26-27, 2023)
General
Stem Cell Transplant for SCD – Dr. Mohsen Alzahrani (May 26-27, 2023)
Watched
General
2024
Stem Cell Transplant for SCD – Dr. Mohsen Alzahrani (May 26-27, 2023)
CAR T Cell Academic Manufacturing – Dr. Manuel Juan (May 26-27, 2023)
General
CAR T Cell Academic Manufacturing – Dr. Manuel Juan (May 26-27, 2023)
Watched
General
2024
CAR T Cell Academic Manufacturing – Dr. Manuel Juan (May 26-27, 2023)
ALL, who should not be transplanted? – Dr. Sebastian Giebel (May 26-27, 2023)
General
ALL, who should not be transplanted? – Dr. Sebastian Giebel (May 26-27, 2023)
Watched
General
2024
ALL, who should not be transplanted? – Dr. Sebastian Giebel (May 26-27, 2023)
Latest Advances in MDS – Dr. Marie Robin (May 26-27, 2023)
General
Latest Advances in MDS – Dr. Marie Robin (May 26-27, 2023)
Watched
General
2024
Latest Advances in MDS – Dr. Marie Robin (May 26-27, 2023)
Latest Advances in Myelofibrosis – Dr. Nicolaus Kroger (May 26-27, 2023)
General
Latest Advances in Myelofibrosis – Dr. Nicolaus Kroger (May 26-27, 2023)
Watched
General
2024
Latest Advances in Myelofibrosis – Dr. Nicolaus Kroger (May 26-27, 2023)
Will CAR T-Cell Therapy Replace Autologous SCT in Multiple Myeloma–Dr. Mohamad Mohty(May26-27, 2023)
General
Will CAR T-Cell Therapy Replace Autologous SCT in Multiple Myeloma–Dr. Mohamad Mohty(May26-27, 2023)
Watched
General
2024
Will CAR T-Cell Therapy Replace Autologous SCT in Multiple Myeloma–Dr. Mohamad Mohty(May26-27, 2023)
Phase 1 trials on Cellular Therapy – Dr. Ayman Saad (February 18, 2023)
General
Phase 1 trials on Cellular Therapy – Dr. Ayman Saad (February 18, 2023)
Watched
General
2024
Phase 1 trials on Cellular Therapy – Dr. Ayman Saad (February 18, 2023)
Involvement of Clinicians in Basic Science Research – Dr. Mohammed Almakadi (February 18, 2023)
General
Involvement of Clinicians in Basic Science Research – Dr. Mohammed Almakadi (February 18, 2023)
Watched
General
2024
Involvement of Clinicians in Basic Science Research – Dr. Mohammed Almakadi (February 18, 2023)
Role of community and companies in supporting research – Dr. Hani Alhashmi (February 18, 2023)
General
Role of community and companies in supporting research – Dr. Hani Alhashmi (February 18, 2023)
Watched
General
2023
Role of community and companies in supporting research – Dr. Hani Alhashmi (February 18, 2023)
Randomized Clinical Trials in Saudi Arabia – Dr. Mansoor Radwi (February 18, 2023)
General
Randomized Clinical Trials in Saudi Arabia – Dr. Mansoor Radwi (February 18, 2023)
Watched
General
2023
Randomized Clinical Trials in Saudi Arabia – Dr. Mansoor Radwi (February 18, 2023)
Academic Integrity & Manuscript Writing – Dr. Ali Hajeer (February 18, 2023)
General
Academic Integrity & Manuscript Writing – Dr. Ali Hajeer (February 18, 2023)
Watched
General
2023
Academic Integrity & Manuscript Writing – Dr. Ali Hajeer (February 18, 2023)
Scientific Writing – Dr. Naila Shaheen (February 18, 2023)
General
Scientific Writing – Dr. Naila Shaheen (February 18, 2023)
Watched
General
2023
Scientific Writing – Dr. Naila Shaheen (February 18, 2023)
Hematological Indices in the Adult Saudi Population – Dr. Naila Shaheen (February 18, 2023)
General
Hematological Indices in the Adult Saudi Population – Dr. Naila Shaheen (February 18, 2023)
Watched
General
2023
Hematological Indices in the Adult Saudi Population – Dr. Naila Shaheen (February 18, 2023)
Improved Survival of Adolecents &Young Adults Pts Aged 14-40 Yrs – Dr.Chokri Ben Lamine(Feb18, 2023)
General
Improved Survival of Adolecents &Young Adults Pts Aged 14-40 Yrs – Dr.Chokri Ben Lamine(Feb18, 2023)
Watched
General
2023
Improved Survival of Adolecents &Young Adults Pts Aged 14-40 Yrs – Dr.Chokri Ben Lamine(Feb18, 2023)
King Khalid University Hospital Lymphoid Database – Dr. Musa Alzahrani (February 18, 2023)
General
King Khalid University Hospital Lymphoid Database – Dr. Musa Alzahrani (February 18, 2023)
Watched
General
2023
King Khalid University Hospital Lymphoid Database – Dr. Musa Alzahrani (February 18, 2023)
Challenges in Starting and Maintaining Research Database – Dr. Ali Farsi (February 18, 2023)
General
Challenges in Starting and Maintaining Research Database – Dr. Ali Farsi (February 18, 2023)
Watched
General
2023
Challenges in Starting and Maintaining Research Database – Dr. Ali Farsi (February 18, 2023)
Overview of the Current Ongoing Clinical Trials at KAMC-Riyadh-Dr. Abdulrahman Raizah (Feb 18, 2023)
General
Overview of the Current Ongoing Clinical Trials at KAMC-Riyadh-Dr. Abdulrahman Raizah (Feb 18, 2023)
Watched
General
2023
Overview of the Current Ongoing Clinical Trials at KAMC-Riyadh-Dr. Abdulrahman Raizah (Feb 18, 2023)
Transplant Donor Consent & Dual Roles: A Case Study in Ethical Dilemmas– Dr. Rosa Gasas(Feb18, 2023)
General
Transplant Donor Consent & Dual Roles: A Case Study in Ethical Dilemmas– Dr. Rosa Gasas(Feb18, 2023)
Watched
General
2023
Transplant Donor Consent & Dual Roles: A Case Study in Ethical Dilemmas– Dr. Rosa Gasas(Feb18, 2023)
INVENT-VTE Intl. Network of Venous Thromboembolism Clinical Research Networks–Dr. Gregoire Le Gal
General
INVENT-VTE Intl. Network of Venous Thromboembolism Clinical Research Networks–Dr. Gregoire Le Gal
Watched
General
2023
INVENT-VTE Intl. Network of Venous Thromboembolism Clinical Research Networks–Dr. Gregoire Le Gal
Advances in Hematology Molecular Diagnostic – Dr. Saeed Alturki (Sep 30-Oct 1, 2022)
General
Advances in Hematology Molecular Diagnostic – Dr. Saeed Alturki (Sep 30-Oct 1, 2022)
Watched
General
2023
Advances in Hematology Molecular Diagnostic – Dr. Saeed Alturki (Sep 30-Oct 1, 2022)
Development of CBC-based Thresholds for Rational JAK2 &BCR:ABL1 Testing–Dr.David Conrad-Sep30Oct1'22
General
Development of CBC-based Thresholds for Rational JAK2 &BCR:ABL1 Testing–Dr.David Conrad-Sep30Oct1'22
Watched
General
2023
Development of CBC-based Thresholds for Rational JAK2 &BCR:ABL1 Testing–Dr.David Conrad-Sep30Oct1'22
International Changes in Donor Elig. Criteria in Regards to Risks of HIVand CJD–Dr. Hanadi AlJedani
General
International Changes in Donor Elig. Criteria in Regards to Risks of HIVand CJD–Dr. Hanadi AlJedani
Watched
General
2023
International Changes in Donor Elig. Criteria in Regards to Risks of HIVand CJD–Dr. Hanadi AlJedani
Patient Blood Management – Dr. Klaus Goerlinger (Sep 30-Oct 1, 2022)
General
Patient Blood Management – Dr. Klaus Goerlinger (Sep 30-Oct 1, 2022)
Watched
General
2023
Patient Blood Management – Dr. Klaus Goerlinger (Sep 30-Oct 1, 2022)
WHO Update on Myeloid Neoplasms – Dr. Nahlah Alghasham (Sep 30-Oct 1, 2022)
General
WHO Update on Myeloid Neoplasms – Dr. Nahlah Alghasham (Sep 30-Oct 1, 2022)
Watched
General
2023
WHO Update on Myeloid Neoplasms – Dr. Nahlah Alghasham (Sep 30-Oct 1, 2022)
An Update on Histiocytic/Dendritic Neoplasms w/Clinical Case Scenarios-Dr.Ghaleb Elyamany(Oct1,2022)
General
An Update on Histiocytic/Dendritic Neoplasms w/Clinical Case Scenarios-Dr.Ghaleb Elyamany(Oct1,2022)
Watched
General
2023
An Update on Histiocytic/Dendritic Neoplasms w/Clinical Case Scenarios-Dr.Ghaleb Elyamany(Oct1,2022)
Updates on the Classification of Lymphoid Neoplasms – Dr. Saeed Alsheiban (Sep 30-Oct 1, 2022)
General
Updates on the Classification of Lymphoid Neoplasms – Dr. Saeed Alsheiban (Sep 30-Oct 1, 2022)
Watched
General
2023
Updates on the Classification of Lymphoid Neoplasms – Dr. Saeed Alsheiban (Sep 30-Oct 1, 2022)
Challenges in MDS Diagnois – Dr. Haitham Khogeer (Sep 30-Oct 1, 2022)
General
Challenges in MDS Diagnois – Dr. Haitham Khogeer (Sep 30-Oct 1, 2022)
Watched
General
2023
Challenges in MDS Diagnois – Dr. Haitham Khogeer (Sep 30-Oct 1, 2022)
Diagnostic Update in Myeloma – Dr. David Conrad (Sep 30-Oct 1, 2022)
General
Diagnostic Update in Myeloma – Dr. David Conrad (Sep 30-Oct 1, 2022)
Watched
General
2023
Diagnostic Update in Myeloma – Dr. David Conrad (Sep 30-Oct 1, 2022)
Laboratory Testing in Patients Treated with DOACs – Dr. Maher Aljohani (Sep 30-Oct 1, 2022)
General
Laboratory Testing in Patients Treated with DOACs – Dr. Maher Aljohani (Sep 30-Oct 1, 2022)
Watched
General
2023
Laboratory Testing in Patients Treated with DOACs – Dr. Maher Aljohani (Sep 30-Oct 1, 2022)
Hematological Reference Interference (RIs) in Saudi Arabia – Dr. Naila Shaheen (Sep 30-Oct 1, 2022)
General
Hematological Reference Interference (RIs) in Saudi Arabia – Dr. Naila Shaheen (Sep 30-Oct 1, 2022)
Watched
General
2023
Hematological Reference Interference (RIs) in Saudi Arabia – Dr. Naila Shaheen (Sep 30-Oct 1, 2022)
ITP Pathophysiology and Diagnostic Prospective – Dr. Mansour Aljabry (Sep 30-Oct 1, 2022)
General
ITP Pathophysiology and Diagnostic Prospective – Dr. Mansour Aljabry (Sep 30-Oct 1, 2022)
Watched
General
2023
ITP Pathophysiology and Diagnostic Prospective – Dr. Mansour Aljabry (Sep 30-Oct 1, 2022)
Treatment of Relapsed/Refractory CCL - Dr. John Gribben (Sep 30-Oct 1, 2022)
General
Treatment of Relapsed/Refractory CCL - Dr. John Gribben (Sep 30-Oct 1, 2022)
Watched
General
2023
Treatment of Relapsed/Refractory CCL - Dr. John Gribben (Sep 30-Oct 1, 2022)
Advance Stage Hodgkin Lymphoma 2022 - Dr. Craig Moskowitz (Sep 30-Oct 1, 2022)
General
Advance Stage Hodgkin Lymphoma 2022 - Dr. Craig Moskowitz (Sep 30-Oct 1, 2022)
Watched
General
2023
Advance Stage Hodgkin Lymphoma 2022 - Dr. Craig Moskowitz (Sep 30-Oct 1, 2022)
CTCL: Evolving Role of Novel Treatments - Dr. Owen O'connor (Sep 30-Oct 1, 2022)
General
CTCL: Evolving Role of Novel Treatments - Dr. Owen O'connor (Sep 30-Oct 1, 2022)
Watched
General
2023
CTCL: Evolving Role of Novel Treatments - Dr. Owen O'connor (Sep 30-Oct 1, 2022)
CAR T-CELL Therapy in DLBCL, When and Which? - Dr. Michael Williams (Sep 30-Oct 1, 2022)
General
CAR T-CELL Therapy in DLBCL, When and Which? - Dr. Michael Williams (Sep 30-Oct 1, 2022)
Watched
General
2023
CAR T-CELL Therapy in DLBCL, When and Which? - Dr. Michael Williams (Sep 30-Oct 1, 2022)
Multiple Myeloma, how to sequence new therapies - Dr. Jesus Berdeja (Sep 30-Oct 1, 2022)
General
Multiple Myeloma, how to sequence new therapies - Dr. Jesus Berdeja (Sep 30-Oct 1, 2022)
Watched
General
2023
Multiple Myeloma, how to sequence new therapies - Dr. Jesus Berdeja (Sep 30-Oct 1, 2022)
Upfront Therapy in DLBCL : R-CHOP and Beyond - Dr. Brian Hill (Sep 30-Oct 1, 2022)
General
Upfront Therapy in DLBCL : R-CHOP and Beyond - Dr. Brian Hill (Sep 30-Oct 1, 2022)
Watched
General
2023
Upfront Therapy in DLBCL : R-CHOP and Beyond - Dr. Brian Hill (Sep 30-Oct 1, 2022)
CAR T-CELL Therapy in Multiple Myeloma, When & How Effective - Dr. Jesus Berdeja(Sep 30-Oct 1, 2022)
General
CAR T-CELL Therapy in Multiple Myeloma, When & How Effective - Dr. Jesus Berdeja(Sep 30-Oct 1, 2022)
Watched
General
2023
CAR T-CELL Therapy in Multiple Myeloma, When & How Effective - Dr. Jesus Berdeja(Sep 30-Oct 1, 2022)
Outcomes of High Dose Methotrexate for CNS Prophylaxis - Dr. Mubarak Almansour (Sep 30-Oct 1, 2022)
General
Outcomes of High Dose Methotrexate for CNS Prophylaxis - Dr. Mubarak Almansour (Sep 30-Oct 1, 2022)
Watched
General
2023
Outcomes of High Dose Methotrexate for CNS Prophylaxis - Dr. Mubarak Almansour (Sep 30-Oct 1, 2022)
Role of Allogenic Transplant in Lymphoma and Local Experience from KAMC-RIYADH - Dr. Mohsen AlZarani
General
Role of Allogenic Transplant in Lymphoma and Local Experience from KAMC-RIYADH - Dr. Mohsen AlZarani
Watched
General
2023
Role of Allogenic Transplant in Lymphoma and Local Experience from KAMC-RIYADH - Dr. Mohsen AlZarani
Outpatient Fractionated ICE Protocol in Relapsed/Refractory Lymphomas - Dr. Reyad Dada
General
Outpatient Fractionated ICE Protocol in Relapsed/Refractory Lymphomas - Dr. Reyad Dada
Watched
General
2023
Outpatient Fractionated ICE Protocol in Relapsed/Refractory Lymphomas - Dr. Reyad Dada
Local Experience in Managing Lymphoma & Myeloma -PMBNH, Jizan -Dr. Fahad Bahkali(Sep 30-Oct 1, 2022)
General
Local Experience in Managing Lymphoma & Myeloma -PMBNH, Jizan -Dr. Fahad Bahkali(Sep 30-Oct 1, 2022)
Watched
General
2023
Local Experience in Managing Lymphoma & Myeloma -PMBNH, Jizan -Dr. Fahad Bahkali(Sep 30-Oct 1, 2022)
Novel Therapies for PTCL - Dr. Owen O'Conner (Sep 30-Oct 1, 2022)
General
Novel Therapies for PTCL - Dr. Owen O'Conner (Sep 30-Oct 1, 2022)
Watched
General
2023
Novel Therapies for PTCL - Dr. Owen O'Conner (Sep 30-Oct 1, 2022)
Autologous PBSC Mobilization &Collection in Patients w/ Lymphoma & Multiple Myeloma -Dr. Ahmad Saeed
General
Autologous PBSC Mobilization &Collection in Patients w/ Lymphoma & Multiple Myeloma -Dr. Ahmad Saeed
Watched
General
2023
Autologous PBSC Mobilization &Collection in Patients w/ Lymphoma & Multiple Myeloma -Dr. Ahmad Saeed
Supportive Care in GVHD - Ms. Zenaida Peric (June 3-4, 2022)
General
Supportive Care in GVHD - Ms. Zenaida Peric (June 3-4, 2022)
Watched
General
2023
Supportive Care in GVHD - Ms. Zenaida Peric (June 3-4, 2022)
Mobilization in Stem Cell Donors: The Basics and Points of Attention - Ms. Charlotte Mestdagh
General
Mobilization in Stem Cell Donors: The Basics and Points of Attention - Ms. Charlotte Mestdagh
Watched
General
2023
Mobilization in Stem Cell Donors: The Basics and Points of Attention - Ms. Charlotte Mestdagh
Prophylactic Medications, Nurses Perspective - Ms. Sandra Schoenfled -(June 3-4, 2022)
General
Prophylactic Medications, Nurses Perspective - Ms. Sandra Schoenfled -(June 3-4, 2022)
Watched
General
2023
Prophylactic Medications, Nurses Perspective - Ms. Sandra Schoenfled -(June 3-4, 2022)
Challenge for Nurses: Minor Donors - Ms. Eugene Trigoso (June 3-4, 2022)
General
Challenge for Nurses: Minor Donors - Ms. Eugene Trigoso (June 3-4, 2022)
Watched
General
2023
Challenge for Nurses: Minor Donors - Ms. Eugene Trigoso (June 3-4, 2022)
KFSH-D Autologous Outpatient HSCT Nursing Experience - Ms. Jennifer Bacal (June 3-4, 2022)
General
KFSH-D Autologous Outpatient HSCT Nursing Experience - Ms. Jennifer Bacal (June 3-4, 2022)
Watched
General
2023
KFSH-D Autologous Outpatient HSCT Nursing Experience - Ms. Jennifer Bacal (June 3-4, 2022)
Reducing Antithymocyte Globulin(ATG) Infusion Related Reaction -Ms. Sudha Alkhraisat(June 3-4, 2022)
General
Reducing Antithymocyte Globulin(ATG) Infusion Related Reaction -Ms. Sudha Alkhraisat(June 3-4, 2022)
Watched
General
2023
Reducing Antithymocyte Globulin(ATG) Infusion Related Reaction -Ms. Sudha Alkhraisat(June 3-4, 2022)
Hematology Outreach Program, Pivotal Role of CNC - Ms. Analia Estanislao (June 3-4, 2022)
General
Hematology Outreach Program, Pivotal Role of CNC - Ms. Analia Estanislao (June 3-4, 2022)
Watched
General
2023
Hematology Outreach Program, Pivotal Role of CNC - Ms. Analia Estanislao (June 3-4, 2022)
King Khalid University Hospital - Riyadh Journey for BMT - Mr. Osama Zamel (June 3-4, 2022)
General
King Khalid University Hospital - Riyadh Journey for BMT - Mr. Osama Zamel (June 3-4, 2022)
Watched
General
2023
King Khalid University Hospital - Riyadh Journey for BMT - Mr. Osama Zamel (June 3-4, 2022)
In the Flight against aTTP - Prof. Dr. Paul Coppo (June 3-4, 2022)
General
In the Flight against aTTP - Prof. Dr. Paul Coppo (June 3-4, 2022)
Watched
General
2023
In the Flight against aTTP - Prof. Dr. Paul Coppo (June 3-4, 2022)
Allogenic Transplantation in Relapsed Refractory AML & Maintenance -Dr. Ahmad Alotaibi(Jun 3-4' 22)
General
Allogenic Transplantation in Relapsed Refractory AML & Maintenance -Dr. Ahmad Alotaibi(Jun 3-4' 22)
Watched
General
2023
Allogenic Transplantation in Relapsed Refractory AML & Maintenance -Dr. Ahmad Alotaibi(Jun 3-4' 22)
Post-transplant Long Term Care - Ms. Michelle Kenyon (June 3-4, 2022)
General
Post-transplant Long Term Care - Ms. Michelle Kenyon (June 3-4, 2022)
Watched
General
2023
Post-transplant Long Term Care - Ms. Michelle Kenyon (June 3-4, 2022)
New Trends in Transplantation in 2022 - Dr. Bassim Albeirouti (June 3-4, 2022)
General
New Trends in Transplantation in 2022 - Dr. Bassim Albeirouti (June 3-4, 2022)
Watched
General
2023
New Trends in Transplantation in 2022 - Dr. Bassim Albeirouti (June 3-4, 2022)
Post-transplant Short Term Care - Ms. Amani Alharbi (June 3-4, 2022)
General
Post-transplant Short Term Care - Ms. Amani Alharbi (June 3-4, 2022)
Watched
General
2023
Post-transplant Short Term Care - Ms. Amani Alharbi (June 3-4, 2022)
How do we choose the best donor for T-cell-replete, HLA-haploidentical Trans. -Mr. Belal Al Blowe
General
How do we choose the best donor for T-cell-replete, HLA-haploidentical Trans. -Mr. Belal Al Blowe
Watched
General
2023
How do we choose the best donor for T-cell-replete, HLA-haploidentical Trans. -Mr. Belal Al Blowe
ABO Incompatible in HSCT - Dr. Ahmed Al Bahrani (June 3-4, 2022)
General
ABO Incompatible in HSCT - Dr. Ahmed Al Bahrani (June 3-4, 2022)
Watched
General
2023
ABO Incompatible in HSCT - Dr. Ahmed Al Bahrani (June 3-4, 2022)
SSBMT Webinar Series (Re-Shaping CML #4) - 03 December 2023
Webinar
SSBMT Webinar Series (Re-Shaping CML #4) - 03 December 2023
Watched
Webinar
2023
SSBMT Webinar Series (Re-Shaping CML #4) - 03 December 2023
Management of Relapsed Refractory FLT3 AML - Dr. Ayman Hejazi (June 3-4, 2022)
General
Management of Relapsed Refractory FLT3 AML - Dr. Ayman Hejazi (June 3-4, 2022)
Watched
General
2023
Management of Relapsed Refractory FLT3 AML - Dr. Ayman Hejazi (June 3-4, 2022)
Goal is to Cure: Transplant vs Gene Therapy for Sickle Cell Disease & Thalassemia - Dr. Rabi Hanna
General
Goal is to Cure: Transplant vs Gene Therapy for Sickle Cell Disease & Thalassemia - Dr. Rabi Hanna
Watched
General
2023
Goal is to Cure: Transplant vs Gene Therapy for Sickle Cell Disease & Thalassemia - Dr. Rabi Hanna
Management of Infectious Complications in HCT - Dr. Rafael dela Camara (June 3-4, 2022)
General
Management of Infectious Complications in HCT - Dr. Rafael dela Camara (June 3-4, 2022)
Watched
General
2023
Management of Infectious Complications in HCT - Dr. Rafael dela Camara (June 3-4, 2022)
Isatuximab Role in RRMM - Dr. Elisabet Manasanch (June 3-4, 2022)
General
Isatuximab Role in RRMM - Dr. Elisabet Manasanch (June 3-4, 2022)
Watched
General
2023
Isatuximab Role in RRMM - Dr. Elisabet Manasanch (June 3-4, 2022)
CAR T-Cell in ALL - Dr. Eolia Brissot (June 3-4, 2022)
General
CAR T-Cell in ALL - Dr. Eolia Brissot (June 3-4, 2022)
Watched
General
2023
CAR T-Cell in ALL - Dr. Eolia Brissot (June 3-4, 2022)
CAR T-Cell in Multiple Myeloma - Dr. Mohamad Mohty (June 3-4, 2022)
General
CAR T-Cell in Multiple Myeloma - Dr. Mohamad Mohty (June 3-4, 2022)
Watched
General
2023
CAR T-Cell in Multiple Myeloma - Dr. Mohamad Mohty (June 3-4, 2022)
CAR T-Cell in Lymphoma - Dr. Anna Sureda (June 3-4, 2022)
General
CAR T-Cell in Lymphoma - Dr. Anna Sureda (June 3-4, 2022)
Watched
General
2023
CAR T-Cell in Lymphoma - Dr. Anna Sureda (June 3-4, 2022)
HSCT in Patients w/ Hemoglobinopathies - Dr. Eolia Brissot (June 3-4, 2022)
General
HSCT in Patients w/ Hemoglobinopathies - Dr. Eolia Brissot (June 3-4, 2022)
Watched
General
2023
HSCT in Patients w/ Hemoglobinopathies - Dr. Eolia Brissot (June 3-4, 2022)
SSBMT Webinar - Re-Shaping CML Series (#3) - 01 November 2023
Webinar
SSBMT Webinar - Re-Shaping CML Series (#3) - 01 November 2023
Watched
Webinar
2023
SSBMT Webinar - Re-Shaping CML Series (#3) - 01 November 2023
SSBMT Webinar (Re-Shaping CML Series) - 02 October 2023
Webinar
SSBMT Webinar (Re-Shaping CML Series) - 02 October 2023
Watched
Webinar
2023
SSBMT Webinar (Re-Shaping CML Series) - 02 October 2023
Hematopathology Overview 2023
General
Hematopathology Overview 2023
Watched
General
2023
Hematopathology Overview 2023
17-ICML Highlights 2023
General
17-ICML Highlights 2023
Watched
General
2023
17-ICML Highlights 2023
Annual Conference of the SS BMT 2023
General
Annual Conference of the SS BMT 2023
Watched
General
2023
Annual Conference of the SS BMT 2023
SSBMT Webinar Series - Re-Shaping CML
Webinar
SSBMT Webinar Series - Re-Shaping CML
Watched
Webinar
2023
SSBMT Webinar Series - Re-Shaping CML
Annual Conference of the SS BMT 2023
General
Annual Conference of the SS BMT 2023
Watched
General
2023
Annual Conference of the SS BMT 2023
Annual Conference of the SS BMT 2023
General
Annual Conference of the SS BMT 2023
Watched
General
2023
Annual Conference of the SS BMT 2023
Annual Conference of the SS BMT 2023
General
Annual Conference of the SS BMT 2023
Watched
General
2023
Annual Conference of the SS BMT 2023
Novel therapies for GVHD - Zinaida Peric (June 3-4, 2022)
General
Novel therapies for GVHD - Zinaida Peric (June 3-4, 2022)
Watched
General
2022
Novel therapies for GVHD - Zinaida Peric (June 3-4, 2022)
AML: selected abstracts - Frederic Baron (June 3-4, 2022)
General
AML: selected abstracts - Frederic Baron (June 3-4, 2022)
Watched
General
2022
AML: selected abstracts - Frederic Baron (June 3-4, 2022)
MDS/SAA: selected abstracts - Regis Peffault de la Tour (June 3-4, 2022)
General
MDS/SAA: selected abstracts - Regis Peffault de la Tour (June 3-4, 2022)
Watched
General
2022
MDS/SAA: selected abstracts - Regis Peffault de la Tour (June 3-4, 2022)
ALL: selected abstracts - Sebastian Giebel (June 3-4, 2022)
General
ALL: selected abstracts - Sebastian Giebel (June 3-4, 2022)
Watched
General
2022
ALL: selected abstracts - Sebastian Giebel (June 3-4, 2022)
Autologous Stem Cell Transplantation for MM – Eastern Province Experience - Khalid Alanazi
General
Autologous Stem Cell Transplantation for MM – Eastern Province Experience - Khalid Alanazi
Watched
General
2022
Autologous Stem Cell Transplantation for MM – Eastern Province Experience - Khalid Alanazi
AML : Single center Experience - Ahmed Hegazi
General
AML : Single center Experience - Ahmed Hegazi
Watched
General
2022
AML : Single center Experience - Ahmed Hegazi
Toxicity analysis of single center experience with AVD-Bv - Amjad Al Thobaiti
General
Toxicity analysis of single center experience with AVD-Bv - Amjad Al Thobaiti
Watched
General
2022
Toxicity analysis of single center experience with AVD-Bv - Amjad Al Thobaiti
New horizons on CLL management - Paolo Ghia (11-12 Feb 2022)
General
New horizons on CLL management - Paolo Ghia (11-12 Feb 2022)
Watched
General
2022
New horizons on CLL management - Paolo Ghia (11-12 Feb 2022)
Human placental mesenchymal stem/stromal cells (pMSCs)inhibit agonist - Tanvir Khatlani
General
Human placental mesenchymal stem/stromal cells (pMSCs)inhibit agonist - Tanvir Khatlani
Watched
General
2022
Human placental mesenchymal stem/stromal cells (pMSCs)inhibit agonist - Tanvir Khatlani
MPNs the Omani experience - Murtadha Khabori (11-12 February 2022)
General
MPNs the Omani experience - Murtadha Khabori (11-12 February 2022)
Watched
General
2022
MPNs the Omani experience - Murtadha Khabori (11-12 February 2022)
The role of electronic health records & disease registries in Hem Research: reality and aspirations
General
The role of electronic health records & disease registries in Hem Research: reality and aspirations
Watched
General
2022
The role of electronic health records & disease registries in Hem Research: reality and aspirations
Patient-reported outcome measures in hematology: what is the best tool? - Mansoor Radwi
General
Patient-reported outcome measures in hematology: what is the best tool? - Mansoor Radwi
Watched
General
2022
Patient-reported outcome measures in hematology: what is the best tool? - Mansoor Radwi
The outcome of COVID-19 infection in Hematology/SCT patients - Riad Elfakih (11-12 Feb 2022)
General
The outcome of COVID-19 infection in Hematology/SCT patients - Riad Elfakih (11-12 Feb 2022)
Watched
General
2022
The outcome of COVID-19 infection in Hematology/SCT patients - Riad Elfakih (11-12 Feb 2022)
Thrombosis in the Setting of COVID-19: data from Saudi Arabia - Abdulrahman Raizah (11-12 February)
General
Thrombosis in the Setting of COVID-19: data from Saudi Arabia - Abdulrahman Raizah (11-12 February)
Watched
General
2022
Thrombosis in the Setting of COVID-19: data from Saudi Arabia - Abdulrahman Raizah (11-12 February)
Reporting deleterious germline variants in hematological disorders: fr where to start? Saeed Alturki
General
Reporting deleterious germline variants in hematological disorders: fr where to start? Saeed Alturki
Watched
General
2022
Reporting deleterious germline variants in hematological disorders: fr where to start? Saeed Alturki
Regulatory approval for clinical trials in hematology: focus in cell and gene therapy - A. Alsayyari
General
Regulatory approval for clinical trials in hematology: focus in cell and gene therapy - A. Alsayyari
Watched
General
2022
Regulatory approval for clinical trials in hematology: focus in cell and gene therapy - A. Alsayyari
SSBMT Live 01 OCT 2022
Live
SSBMT Live 01 OCT 2022
Watched
Live
2022
SSBMT Live 01 OCT 2022
SSBMT Live 01 OCT 2022
Live
SSBMT Live 01 OCT 2022
Watched
Live
2022
SSBMT Live 01 OCT 2022
SSBMT Live 30 SEP 2022
Live
SSBMT Live 30 SEP 2022
Watched
Live
2022
SSBMT Live 30 SEP 2022
MRD testing in AML - Clinical utility - Zeyad Al-Shaibani (DMM) - (11-12 Feb2022)
General
MRD testing in AML - Clinical utility - Zeyad Al-Shaibani (DMM) - (11-12 Feb2022)
Watched
General
2022
MRD testing in AML - Clinical utility - Zeyad Al-Shaibani (DMM) - (11-12 Feb2022)
Clonal hematopoiesis: Silence before Hurricane - Hanan Hamed (EG) - 11-12 Feb2022
General
Clonal hematopoiesis: Silence before Hurricane - Hanan Hamed (EG) - 11-12 Feb2022
Watched
General
2022
Clonal hematopoiesis: Silence before Hurricane - Hanan Hamed (EG) - 11-12 Feb2022
Evolving AML treatment paradigm - Tapan Kadia (USA) (SSBMT/SSH Combined Annual Conf - 11-12 Feb2022)
General
Evolving AML treatment paradigm - Tapan Kadia (USA) (SSBMT/SSH Combined Annual Conf - 11-12 Feb2022)
Watched
General
2022
Evolving AML treatment paradigm - Tapan Kadia (USA) (SSBMT/SSH Combined Annual Conf - 11-12 Feb2022)
Non-double-hit DLBC, should 1st line therapy be changed - Pier Luigi Zinzani (IT) - 11-12 Feb 2022
General
Non-double-hit DLBC, should 1st line therapy be changed - Pier Luigi Zinzani (IT) - 11-12 Feb 2022
Watched
General
2022
Non-double-hit DLBC, should 1st line therapy be changed - Pier Luigi Zinzani (IT) - 11-12 Feb 2022
CNS prophylaxis is indicated for high-grade B-cell lymphoma - Manar Abdulbaqi (DMM) - 11-12 Feb 2022
General
CNS prophylaxis is indicated for high-grade B-cell lymphoma - Manar Abdulbaqi (DMM) - 11-12 Feb 2022
Watched
General
2022
CNS prophylaxis is indicated for high-grade B-cell lymphoma - Manar Abdulbaqi (DMM) - 11-12 Feb 2022
Evolving CLL treatment paradigm - Ahmed Absi (JED) (SSBMT/SSH Combined Annual Conf - 11-12 Feb2022)
General
Evolving CLL treatment paradigm - Ahmed Absi (JED) (SSBMT/SSH Combined Annual Conf - 11-12 Feb2022)
Watched
General
2022
Evolving CLL treatment paradigm - Ahmed Absi (JED) (SSBMT/SSH Combined Annual Conf - 11-12 Feb2022)
Evolving landscape in management of Relapsed Refractory AML - Syed Osman (RUH) - 11-12 Feb2022
General
Evolving landscape in management of Relapsed Refractory AML - Syed Osman (RUH) - 11-12 Feb2022
Watched
General
2022
Evolving landscape in management of Relapsed Refractory AML - Syed Osman (RUH) - 11-12 Feb2022
New advances in Hodgkin's Lymphoma - Jonathan Friedberg (USA) - (11-12 Feb2022)
General
New advances in Hodgkin's Lymphoma - Jonathan Friedberg (USA) - (11-12 Feb2022)
Watched
General
2022
New advances in Hodgkin's Lymphoma - Jonathan Friedberg (USA) - (11-12 Feb2022)
Tailoring management for patients with Multiple Myeloma in 1st relapse - Ahmed Alhuraiji (KW)
General
Tailoring management for patients with Multiple Myeloma in 1st relapse - Ahmed Alhuraiji (KW)
Watched
General
2022
Tailoring management for patients with Multiple Myeloma in 1st relapse - Ahmed Alhuraiji (KW)
Ways to improve therapy for newly diagnosed Multiple Myeloma - Majed Alahmadi (JED) - 11-12 Feb 2022
General
Ways to improve therapy for newly diagnosed Multiple Myeloma - Majed Alahmadi (JED) - 11-12 Feb 2022
Watched
General
2022
Ways to improve therapy for newly diagnosed Multiple Myeloma - Majed Alahmadi (JED) - 11-12 Feb 2022
How Multiple Myeloma should be treated in 2022 - An update - Mohamad Mohty
General
How Multiple Myeloma should be treated in 2022 - An update - Mohamad Mohty
Watched
General
2022
How Multiple Myeloma should be treated in 2022 - An update - Mohamad Mohty
CAR T-Cell Therapy Role in DLBCL - Sameer Al-Amoudi (JED) - 11-12 Feb 2022
General
CAR T-Cell Therapy Role in DLBCL - Sameer Al-Amoudi (JED) - 11-12 Feb 2022
Watched
General
2022
CAR T-Cell Therapy Role in DLBCL - Sameer Al-Amoudi (JED) - 11-12 Feb 2022
CAR T-cell therapy role in ALL - Nitin Jain (USA) - (SSBMT/SSH Combined Annual Conf - 11-12 Feb2022)
General
CAR T-cell therapy role in ALL - Nitin Jain (USA) - (SSBMT/SSH Combined Annual Conf - 11-12 Feb2022)
Watched
General
2022
CAR T-cell therapy role in ALL - Nitin Jain (USA) - (SSBMT/SSH Combined Annual Conf - 11-12 Feb2022)
How to establish a successful cellular therapy program - Navneet Majhail (USA) - 11-12 Feb2022
General
How to establish a successful cellular therapy program - Navneet Majhail (USA) - 11-12 Feb2022
Watched
General
2022
How to establish a successful cellular therapy program - Navneet Majhail (USA) - 11-12 Feb2022
SSBMT Live Webinar 4 June 2022
Webinar
SSBMT Live Webinar 4 June 2022
Watched
Webinar
2022
SSBMT Live Webinar 4 June 2022
SSBMT Live Webinar
Webinar
SSBMT Live Webinar
Watched
Webinar
2022
SSBMT Live Webinar
SSBMT جمعية الخلايا الجذعية Live Stream
Live
SSBMT جمعية الخلايا الجذعية Live Stream
Watched
Live
2022
SSBMT جمعية الخلايا الجذعية Live Stream
SSBMT Webinar Series - How I Treat CMV infection and disease in HSCT - 18 December 2021
Webinar
SSBMT Webinar Series - How I Treat CMV infection and disease in HSCT - 18 December 2021
Watched
Webinar
2021
SSBMT Webinar Series - How I Treat CMV infection and disease in HSCT - 18 December 2021
New Therapeutics in Non-Hodgkin Lymphoma: Dr. Anastasios Stathis (Switzerland) - 16-ICML Highlights
General
New Therapeutics in Non-Hodgkin Lymphoma: Dr. Anastasios Stathis (Switzerland) - 16-ICML Highlights
Watched
General
2021
New Therapeutics in Non-Hodgkin Lymphoma: Dr. Anastasios Stathis (Switzerland) - 16-ICML Highlights
Chronic Lymphocytic Leukemia : Dr. Davide Rossi (Switzerland) - 16-ICML Highlights - 08 Oct 2021
General
Chronic Lymphocytic Leukemia : Dr. Davide Rossi (Switzerland) - 16-ICML Highlights - 08 Oct 2021
Watched
General
2021
Chronic Lymphocytic Leukemia : Dr. Davide Rossi (Switzerland) - 16-ICML Highlights - 08 Oct 2021
Program Overview: Dr. Mubarak Al Mansour, Chairman,Scientific Committee, 16-ICML Highlights (8Oct21)
General
Program Overview: Dr. Mubarak Al Mansour, Chairman,Scientific Committee, 16-ICML Highlights (8Oct21)
Watched
General
2021
Program Overview: Dr. Mubarak Al Mansour, Chairman,Scientific Committee, 16-ICML Highlights (8Oct21)
Opening Remarks: Prof. Ahmed Alaskar, President, SSBMT on the 16-ICML Highlights (Hybrid event).
General
Opening Remarks: Prof. Ahmed Alaskar, President, SSBMT on the 16-ICML Highlights (Hybrid event).
Watched
General
2021
Opening Remarks: Prof. Ahmed Alaskar, President, SSBMT on the 16-ICML Highlights (Hybrid event).
Lymphoma Imaging - Dr. Emanuele Zucca (Switzerland) - 16-ICML Highlights - 08 Oct 2021
General
Lymphoma Imaging - Dr. Emanuele Zucca (Switzerland) - 16-ICML Highlights - 08 Oct 2021
Watched
General
2021
Lymphoma Imaging - Dr. Emanuele Zucca (Switzerland) - 16-ICML Highlights - 08 Oct 2021
Summary presentation by Dr. Mohsen Al Zahrani (KAMC-Riyadh) - 16-ICML Highlights - 08 October 2021
General
Summary presentation by Dr. Mohsen Al Zahrani (KAMC-Riyadh) - 16-ICML Highlights - 08 October 2021
Watched
General
2021
Summary presentation by Dr. Mohsen Al Zahrani (KAMC-Riyadh) - 16-ICML Highlights - 08 October 2021
Aggressive Lymphomas: Dr. Anastasios Stathis (Switzerland) - 16-ICML Highlights - 08 Oct 2021
General
Aggressive Lymphomas: Dr. Anastasios Stathis (Switzerland) - 16-ICML Highlights - 08 Oct 2021
Watched
General
2021
Aggressive Lymphomas: Dr. Anastasios Stathis (Switzerland) - 16-ICML Highlights - 08 Oct 2021
Optimising outcomes in cutaneous T-cell lymphoma: Dr. Pier Luigi Zinzani (Italy) - 08 Oct 2021
General
Optimising outcomes in cutaneous T-cell lymphoma: Dr. Pier Luigi Zinzani (Italy) - 08 Oct 2021
Watched
General
2021
Optimising outcomes in cutaneous T-cell lymphoma: Dr. Pier Luigi Zinzani (Italy) - 08 Oct 2021
Mantle cell lymphoma induces high response: Dr. Musa Alzahrani (KSU) 16-ICML Highlights -08 Oct 2021
General
Mantle cell lymphoma induces high response: Dr. Musa Alzahrani (KSU) 16-ICML Highlights -08 Oct 2021
Watched
General
2021
Mantle cell lymphoma induces high response: Dr. Musa Alzahrani (KSU) 16-ICML Highlights -08 Oct 2021
Indolent Lymphoma: Dr. Stefano Luminari (Italy) - 16-ICML Highlights - 08 Oct 2021
General
Indolent Lymphoma: Dr. Stefano Luminari (Italy) - 16-ICML Highlights - 08 Oct 2021
Watched
General
2021
Indolent Lymphoma: Dr. Stefano Luminari (Italy) - 16-ICML Highlights - 08 Oct 2021
Summary presentation by Dr. Ahmed Absi (KAMC-Jeddah) - 16-ICML Highlights - 08 Oct 2021
General
Summary presentation by Dr. Ahmed Absi (KAMC-Jeddah) - 16-ICML Highlights - 08 Oct 2021
Watched
General
2021
Summary presentation by Dr. Ahmed Absi (KAMC-Jeddah) - 16-ICML Highlights - 08 Oct 2021
Summary presentation by Dr. John Apostolidis (KFSH-Dammam) - 16-ICML Highlights - 08 October 2021.
General
Summary presentation by Dr. John Apostolidis (KFSH-Dammam) - 16-ICML Highlights - 08 October 2021.
Watched
General
2021
Summary presentation by Dr. John Apostolidis (KFSH-Dammam) - 16-ICML Highlights - 08 October 2021.
Opening /Program Overview: Dr. Ammar Alsughayir (KFMC) - Hematopathology Overview 2021 - 09 Oct 2021
General
Opening /Program Overview: Dr. Ammar Alsughayir (KFMC) - Hematopathology Overview 2021 - 09 Oct 2021
Watched
General
2021
Opening /Program Overview: Dr. Ammar Alsughayir (KFMC) - Hematopathology Overview 2021 - 09 Oct 2021
Large B-cell lymphoma by Dr. Musa Alzahrani (KSU) - 16-ICML Highlights - 08 Oct 2021
General
Large B-cell lymphoma by Dr. Musa Alzahrani (KSU) - 16-ICML Highlights - 08 Oct 2021
Watched
General
2021
Large B-cell lymphoma by Dr. Musa Alzahrani (KSU) - 16-ICML Highlights - 08 Oct 2021
Aggressive Extranodal Entities: Dr. Emanuele Zucca (Switzerland) - 16-ICML Highlights - 08 Oct 2021
General
Aggressive Extranodal Entities: Dr. Emanuele Zucca (Switzerland) - 16-ICML Highlights - 08 Oct 2021
Watched
General
2021
Aggressive Extranodal Entities: Dr. Emanuele Zucca (Switzerland) - 16-ICML Highlights - 08 Oct 2021
Summary presentation by Dr. Riad Elfakih (KFSH-RC, Riyadh) - 16-ICML Highlights - 08 Oct 2021
General
Summary presentation by Dr. Riad Elfakih (KFSH-RC, Riyadh) - 16-ICML Highlights - 08 Oct 2021
Watched
General
2021
Summary presentation by Dr. Riad Elfakih (KFSH-RC, Riyadh) - 16-ICML Highlights - 08 Oct 2021
Peripheral T/NK-Cell Lymphomas: Dr. Stefano Luminari (Italy) 16-ICML Highlights - 08 Oct 2021
General
Peripheral T/NK-Cell Lymphomas: Dr. Stefano Luminari (Italy) 16-ICML Highlights - 08 Oct 2021
Watched
General
2021
Peripheral T/NK-Cell Lymphomas: Dr. Stefano Luminari (Italy) 16-ICML Highlights - 08 Oct 2021
Hematological complications of COVID-19 infection: Mohammed Alsheef- 09 Oct 2021
General
Hematological complications of COVID-19 infection: Mohammed Alsheef- 09 Oct 2021
Watched
General
2021
Hematological complications of COVID-19 infection: Mohammed Alsheef- 09 Oct 2021
MRD Assessment tools in Acute leukemia: Dr. Abdullah Alharbi - Hempath Overview 2021 - 09 Oct 2021
General
MRD Assessment tools in Acute leukemia: Dr. Abdullah Alharbi - Hempath Overview 2021 - 09 Oct 2021
Watched
General
2021
MRD Assessment tools in Acute leukemia: Dr. Abdullah Alharbi - Hempath Overview 2021 - 09 Oct 2021
AML, Diagnostic Approach: Dr. Mansour Aljabry - Hematopathology Overview 2021 - 09 Oct 2021
General
AML, Diagnostic Approach: Dr. Mansour Aljabry - Hematopathology Overview 2021 - 09 Oct 2021
Watched
General
2021
AML, Diagnostic Approach: Dr. Mansour Aljabry - Hematopathology Overview 2021 - 09 Oct 2021
Molecular Pathological findings in neoplastic hematology: Dr. Haitham Khogeer - 09 Oct 2021
General
Molecular Pathological findings in neoplastic hematology: Dr. Haitham Khogeer - 09 Oct 2021
Watched
General
2021
Molecular Pathological findings in neoplastic hematology: Dr. Haitham Khogeer - 09 Oct 2021
Delving Deept into CLL by Dr. Ahmad Alsaeed (KAMC-Jeddah) 16-ICML Highlights - 08 Oct 2021
General
Delving Deept into CLL by Dr. Ahmad Alsaeed (KAMC-Jeddah) 16-ICML Highlights - 08 Oct 2021
Watched
General
2021
Delving Deept into CLL by Dr. Ahmad Alsaeed (KAMC-Jeddah) 16-ICML Highlights - 08 Oct 2021
Test your transfusion medicine Knowledge: Dr. Maha Badawi - Hemapath Overview 2021 - 09 Oct 2021
General
Test your transfusion medicine Knowledge: Dr. Maha Badawi - Hemapath Overview 2021 - 09 Oct 2021
Watched
General
2021
Test your transfusion medicine Knowledge: Dr. Maha Badawi - Hemapath Overview 2021 - 09 Oct 2021
Patient blood management: Dr. Ahmed Albahrani - Hematopathology Overview 2021 - 09 Oct 2021
General
Patient blood management: Dr. Ahmed Albahrani - Hematopathology Overview 2021 - 09 Oct 2021
Watched
General
2021
Patient blood management: Dr. Ahmed Albahrani - Hematopathology Overview 2021 - 09 Oct 2021
Pure red cell aplasia review: Dr. Mona Alfaraj- Hematopathology Overview 2021 - 09 Oct 2021
General
Pure red cell aplasia review: Dr. Mona Alfaraj- Hematopathology Overview 2021 - 09 Oct 2021
Watched
General
2021
Pure red cell aplasia review: Dr. Mona Alfaraj- Hematopathology Overview 2021 - 09 Oct 2021
High-grade B-Cell lymphoma, Case Presentation:Dr. Ghaleb Alyamani - HempathOverview 2021-09 Oct 2021
General
High-grade B-Cell lymphoma, Case Presentation:Dr. Ghaleb Alyamani - HempathOverview 2021-09 Oct 2021
Watched
General
2021
High-grade B-Cell lymphoma, Case Presentation:Dr. Ghaleb Alyamani - HempathOverview 2021-09 Oct 2021
Pregnancy related hemostatic complications: Dr. Sameera Alsafwani - 09 Oct 2021
General
Pregnancy related hemostatic complications: Dr. Sameera Alsafwani - 09 Oct 2021
Watched
General
2021
Pregnancy related hemostatic complications: Dr. Sameera Alsafwani - 09 Oct 2021
NGS in hematolymphoid malignancies: Dr. Saeed Al Turki - - Hempath Overview 2021 - 09 Oct 2021
General
NGS in hematolymphoid malignancies: Dr. Saeed Al Turki - - Hempath Overview 2021 - 09 Oct 2021
Watched
General
2021
NGS in hematolymphoid malignancies: Dr. Saeed Al Turki - - Hempath Overview 2021 - 09 Oct 2021
Impact of Covid-19 on blood supply & transfusion medicine: Dr. Salwa Hindawi - 09 Oct 2021
General
Impact of Covid-19 on blood supply & transfusion medicine: Dr. Salwa Hindawi - 09 Oct 2021
Watched
General
2021
Impact of Covid-19 on blood supply & transfusion medicine: Dr. Salwa Hindawi - 09 Oct 2021
Plasma transfusion, what’s new?: Dr. Ammar Alsughayir - Hematopathology Overview 2021 - 09 Oct 2021
General
Plasma transfusion, what’s new?: Dr. Ammar Alsughayir - Hematopathology Overview 2021 - 09 Oct 2021
Watched
General
2021
Plasma transfusion, what’s new?: Dr. Ammar Alsughayir - Hematopathology Overview 2021 - 09 Oct 2021
SSBMT Webinar Series - Invasive fungal infections’ updates in Hematology Setting - 04 December 2021
Webinar
SSBMT Webinar Series - Invasive fungal infections’ updates in Hematology Setting - 04 December 2021
Watched
Webinar
2021
SSBMT Webinar Series - Invasive fungal infections’ updates in Hematology Setting - 04 December 2021
SSBMT Webinar Series - 27 November 2021
Webinar
SSBMT Webinar Series - 27 November 2021
Watched
Webinar
2021
SSBMT Webinar Series - 27 November 2021
SSBMT Webinar Series - How I Treat AL Amyloidosis - 06 November 2021
Webinar
SSBMT Webinar Series - How I Treat AL Amyloidosis - 06 November 2021
Watched
Webinar
2021
SSBMT Webinar Series - How I Treat AL Amyloidosis - 06 November 2021
SSBMT Webinar - How I Treat MCL in light of new EHA-ICML update - 30 October 2021
Webinar
SSBMT Webinar - How I Treat MCL in light of new EHA-ICML update - 30 October 2021
Watched
Webinar
2021
SSBMT Webinar - How I Treat MCL in light of new EHA-ICML update - 30 October 2021
SSBMT Webinar - How I Treat CLL in light of new EHA update - 16 October 2021
Webinar
SSBMT Webinar - How I Treat CLL in light of new EHA update - 16 October 2021
Watched
Webinar
2021
SSBMT Webinar - How I Treat CLL in light of new EHA update - 16 October 2021
16-ICML Highlights & Hematopathology Overview 2021 - 08-09 October 2021
General
16-ICML Highlights & Hematopathology Overview 2021 - 08-09 October 2021
Watched
General
2021
16-ICML Highlights & Hematopathology Overview 2021 - 08-09 October 2021
16-ICML Highlights & Hematopathology Overview 2021 - 08-09 October 2021
General
16-ICML Highlights & Hematopathology Overview 2021 - 08-09 October 2021
Watched
General
2021
16-ICML Highlights & Hematopathology Overview 2021 - 08-09 October 2021
SSBMT Webinar - 25 September 2021
Webinar
SSBMT Webinar - 25 September 2021
Watched
Webinar
2021
SSBMT Webinar - 25 September 2021
SSBMT WEBINAR SERIES - 18 September 2021
Webinar
SSBMT WEBINAR SERIES - 18 September 2021
Watched
Webinar
2021
SSBMT WEBINAR SERIES - 18 September 2021
SSBMT Webinar Series - 10 July 2021
Webinar
SSBMT Webinar Series - 10 July 2021
Watched
Webinar
2021
SSBMT Webinar Series - 10 July 2021
SSBMT Webinar Series - 26 June 2021
Webinar
SSBMT Webinar Series - 26 June 2021
Watched
Webinar
2021
SSBMT Webinar Series - 26 June 2021
8th Annual Saudi Hematology/Oncology Nurses Conference - 29 May 2021
General
8th Annual Saudi Hematology/Oncology Nurses Conference - 29 May 2021
Watched
General
2021
8th Annual Saudi Hematology/Oncology Nurses Conference - 29 May 2021
10th Annual Conference of SSBMT / EBMT 2021 Highlights - 28 May 2021
General
10th Annual Conference of SSBMT / EBMT 2021 Highlights - 28 May 2021
Watched
General
2021
10th Annual Conference of SSBMT / EBMT 2021 Highlights - 28 May 2021
SSBMT 10-year Overview الجمعية العلمية السعودية لزراعة الخلايا الجذعية - مسيرة 10 سنوات
General
SSBMT 10-year Overview الجمعية العلمية السعودية لزراعة الخلايا الجذعية - مسيرة 10 سنوات
Watched
General
2021
SSBMT 10-year Overview الجمعية العلمية السعودية لزراعة الخلايا الجذعية - مسيرة 10 سنوات
SSBMT Webinar Series - Management of AML – Practical Cases in Saudi Arabia
Webinar
SSBMT Webinar Series - Management of AML – Practical Cases in Saudi Arabia
Watched
Webinar
2021
SSBMT Webinar Series - Management of AML – Practical Cases in Saudi Arabia
SSBMT Webinar Series - 17 April 2021
Webinar
SSBMT Webinar Series - 17 April 2021
Watched
Webinar
2021
SSBMT Webinar Series - 17 April 2021
SSBMT Webinar Series - 10 April 2021
Webinar
SSBMT Webinar Series - 10 April 2021
Watched
Webinar
2021
SSBMT Webinar Series - 10 April 2021
SSBMT Webinar Series - 03 April 2021
Webinar
SSBMT Webinar Series - 03 April 2021
Watched
Webinar
2021
SSBMT Webinar Series - 03 April 2021
SSBMT Webinar Series - 27 March 2021
Webinar
SSBMT Webinar Series - 27 March 2021
Watched
Webinar
2021
SSBMT Webinar Series - 27 March 2021
SSBMT Webinar Series - 20 March
Webinar
SSBMT Webinar Series - 20 March
Watched
Webinar
2021
SSBMT Webinar Series - 20 March
SSBMT Webinar Series - 13 March 2021
Webinar
SSBMT Webinar Series - 13 March 2021
Watched
Webinar
2021
SSBMT Webinar Series - 13 March 2021
SSBMT Webinar Series - 06 March 2021
Webinar
SSBMT Webinar Series - 06 March 2021
Watched
Webinar
2021
SSBMT Webinar Series - 06 March 2021
SSBMT WEBINAR SERIES - 27 February 2021
Webinar
SSBMT WEBINAR SERIES - 27 February 2021
Watched
Webinar
2021
SSBMT WEBINAR SERIES - 27 February 2021
SSBMT Webinar Series - 20 February 2021
Webinar
SSBMT Webinar Series - 20 February 2021
Watched
Webinar
2021
SSBMT Webinar Series - 20 February 2021
SSBMT Webinar Series - 13 February 2021
Webinar
SSBMT Webinar Series - 13 February 2021
Watched
Webinar
2021
SSBMT Webinar Series - 13 February 2021
SSBMT Webinar Series - CAR T-Cell Therapy, current status & future - 06 Feb
Webinar
SSBMT Webinar Series - CAR T-Cell Therapy, current status & future - 06 Feb
Watched
Webinar
2021
SSBMT Webinar Series - CAR T-Cell Therapy, current status & future - 06 Feb
SSBMT Webinar Series - How I Treat Nodular Lymphocyte predominant Hodgkin’s Lymphoma - 30 Jan 2021
Webinar
SSBMT Webinar Series - How I Treat Nodular Lymphocyte predominant Hodgkin’s Lymphoma - 30 Jan 2021
Watched
Webinar
2021
SSBMT Webinar Series - How I Treat Nodular Lymphocyte predominant Hodgkin’s Lymphoma - 30 Jan 2021
SSBMT Webinar Series - How I Treat Myelofibrosis with focus on Stem Cell Transplantation
Webinar
SSBMT Webinar Series - How I Treat Myelofibrosis with focus on Stem Cell Transplantation
Watched
Webinar
2021
SSBMT Webinar Series - How I Treat Myelofibrosis with focus on Stem Cell Transplantation
SSBMT Webinar Series - How I Treat Pediatric ITP based on ASH Guidelines - 09 January 2021
Webinar
SSBMT Webinar Series - How I Treat Pediatric ITP based on ASH Guidelines - 09 January 2021
Watched
Webinar
2021
SSBMT Webinar Series - How I Treat Pediatric ITP based on ASH Guidelines - 09 January 2021
SSBMT Webinar on How I Treat Refractory/Relapsed Hodgkin's Lymphoma - 26 December
Webinar
SSBMT Webinar on How I Treat Refractory/Relapsed Hodgkin's Lymphoma - 26 December
Watched
Webinar
2020
SSBMT Webinar on How I Treat Refractory/Relapsed Hodgkin's Lymphoma - 26 December
SSBMT Webinar Series on How I Treat AML incorporating Novel Agents - 19 December 2020
Webinar
SSBMT Webinar Series on How I Treat AML incorporating Novel Agents - 19 December 2020
Watched
Webinar
2020
SSBMT Webinar Series on How I Treat AML incorporating Novel Agents - 19 December 2020
SSBMT Webinar Series on How I Treat Severe Aplastic Anemia Refractory to Immunosuppression - 12 Dec
Webinar
SSBMT Webinar Series on How I Treat Severe Aplastic Anemia Refractory to Immunosuppression - 12 Dec
Watched
Webinar
2020
SSBMT Webinar Series on How I Treat Severe Aplastic Anemia Refractory to Immunosuppression - 12 Dec
SSBMT Webinar Series - What’s the latest in CAR-T and Bi-specifics for Multiple Myeloma - 02 Dec '20
Webinar
SSBMT Webinar Series - What’s the latest in CAR-T and Bi-specifics for Multiple Myeloma - 02 Dec '20
Watched
Webinar
2020
SSBMT Webinar Series - What’s the latest in CAR-T and Bi-specifics for Multiple Myeloma - 02 Dec '20
SSBMT Webinar Series - How I Treat PV/ET beyond Hydroxyurea - 28 November 2020
Webinar
SSBMT Webinar Series - How I Treat PV/ET beyond Hydroxyurea - 28 November 2020
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat PV/ET beyond Hydroxyurea - 28 November 2020
SSBMT Webinar Series - How I Treat Thrombotic Thrombocytopenic Purpura (TTP) - 21 November
Webinar
SSBMT Webinar Series - How I Treat Thrombotic Thrombocytopenic Purpura (TTP) - 21 November
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat Thrombotic Thrombocytopenic Purpura (TTP) - 21 November
SSBMT Webinar Series - How I Treat AML incorporating MRD assessments - 14 November
Webinar
SSBMT Webinar Series - How I Treat AML incorporating MRD assessments - 14 November
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat AML incorporating MRD assessments - 14 November
SSBMT Webinar Series - How I Treat Chronic GVHD - 07 November 2020
Webinar
SSBMT Webinar Series - How I Treat Chronic GVHD - 07 November 2020
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat Chronic GVHD - 07 November 2020
SSBMT Webinar Series - Managing fungal infections with hem malignancies - 31 Oct
Webinar
SSBMT Webinar Series - Managing fungal infections with hem malignancies - 31 Oct
Watched
Webinar
2020
SSBMT Webinar Series - Managing fungal infections with hem malignancies - 31 Oct
SSBMT Webinar Series - How I Treat Refractory ITP with Dr. Waleed Ghanima of University of Oslo
Webinar
SSBMT Webinar Series - How I Treat Refractory ITP with Dr. Waleed Ghanima of University of Oslo
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat Refractory ITP with Dr. Waleed Ghanima of University of Oslo
SSBMT WEBINAR Series - How I Treat Newly diagnosed Chronic Myeloid Leukemia - 17 October 2020
Webinar
SSBMT WEBINAR Series - How I Treat Newly diagnosed Chronic Myeloid Leukemia - 17 October 2020
Watched
Webinar
2020
SSBMT WEBINAR Series - How I Treat Newly diagnosed Chronic Myeloid Leukemia - 17 October 2020
SSBMT Webinar Series - How I Treat Low to Intermediate Risk MDS - 10 Oct 2020
Webinar
SSBMT Webinar Series - How I Treat Low to Intermediate Risk MDS - 10 Oct 2020
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat Low to Intermediate Risk MDS - 10 Oct 2020
SSBMT Webinar Series - How I Treat Multiple Myeloma in Relapsed Post-Auto SCT - 03 October
Webinar
SSBMT Webinar Series - How I Treat Multiple Myeloma in Relapsed Post-Auto SCT - 03 October
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat Multiple Myeloma in Relapsed Post-Auto SCT - 03 October
SSBMT Webinar Series - How I Treat Cutaneous T-Cell Lymphoma - 26 Sep 2020
Webinar
SSBMT Webinar Series - How I Treat Cutaneous T-Cell Lymphoma - 26 Sep 2020
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat Cutaneous T-Cell Lymphoma - 26 Sep 2020
SSBMT Webinar Series - How I Treat Newly diagnosed Chronic Lymphocytic Leukemia - 19 Sept 2020
Webinar
SSBMT Webinar Series - How I Treat Newly diagnosed Chronic Lymphocytic Leukemia - 19 Sept 2020
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat Newly diagnosed Chronic Lymphocytic Leukemia - 19 Sept 2020
SSBMT Webinar Series - How I Treat Sickle Cell Disease with recurrent VOCs - 12 September
Webinar
SSBMT Webinar Series - How I Treat Sickle Cell Disease with recurrent VOCs - 12 September
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat Sickle Cell Disease with recurrent VOCs - 12 September
SSBMT Webinar Series - How I Treat Multiple Myeloma and What's the latest? - 05 September 2020
Webinar
SSBMT Webinar Series - How I Treat Multiple Myeloma and What's the latest? - 05 September 2020
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat Multiple Myeloma and What's the latest? - 05 September 2020
Is Warfarin Dead as a Treatment for New Venous Thromboembolism, Yes or No - 29 August 2020
General
Is Warfarin Dead as a Treatment for New Venous Thromboembolism, Yes or No - 29 August 2020
Watched
General
2020
Is Warfarin Dead as a Treatment for New Venous Thromboembolism, Yes or No - 29 August 2020
SSBMT Webinar - How I Treat Multiple Myeloma Post-Auto SCT - Should we give consolidation? 22 August
Webinar
SSBMT Webinar - How I Treat Multiple Myeloma Post-Auto SCT - Should we give consolidation? 22 August
Watched
Webinar
2020
SSBMT Webinar - How I Treat Multiple Myeloma Post-Auto SCT - Should we give consolidation? 22 August
SSBMT Webinar Series - How I Treat Multiple Myeloma Post-Auto SCT - Should we give consolidation?
Webinar
SSBMT Webinar Series - How I Treat Multiple Myeloma Post-Auto SCT - Should we give consolidation?
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat Multiple Myeloma Post-Auto SCT - Should we give consolidation?
SSBMT Webinar - How I Treat Ph+ ALL in Adult Post-CR1? Allo-SCT, Yes or No
Webinar
SSBMT Webinar - How I Treat Ph+ ALL in Adult Post-CR1? Allo-SCT, Yes or No
Watched
Webinar
2020
SSBMT Webinar - How I Treat Ph+ ALL in Adult Post-CR1? Allo-SCT, Yes or No
SSBMT WEBINAR Series - How I Treat CML who failed prior therapy - 25 July 2020
Webinar
SSBMT WEBINAR Series - How I Treat CML who failed prior therapy - 25 July 2020
Watched
Webinar
2020
SSBMT WEBINAR Series - How I Treat CML who failed prior therapy - 25 July 2020
SSBMT Webinar Series - How I Treat Acute Myeloid Leukemia with Prof. Richard Larson - 18 July 2020
Webinar
SSBMT Webinar Series - How I Treat Acute Myeloid Leukemia with Prof. Richard Larson - 18 July 2020
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat Acute Myeloid Leukemia with Prof. Richard Larson - 18 July 2020
How I Treat Acute Myeloid Leukemia - 18 July 2020
General
How I Treat Acute Myeloid Leukemia - 18 July 2020
Watched
General
2020
How I Treat Acute Myeloid Leukemia - 18 July 2020
SSBMT Webinar Series - How I Treat Newly diagnosed Advanced stage Hodgkin's Lymphoma - 11 July 2020
Webinar
SSBMT Webinar Series - How I Treat Newly diagnosed Advanced stage Hodgkin's Lymphoma - 11 July 2020
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat Newly diagnosed Advanced stage Hodgkin's Lymphoma - 11 July 2020
SSBMT Webinar Series - How I Treat Newly diagnosed Advanced Stage Hodgkins Lymphoma - 11 July 2020
Webinar
SSBMT Webinar Series - How I Treat Newly diagnosed Advanced Stage Hodgkins Lymphoma - 11 July 2020
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat Newly diagnosed Advanced Stage Hodgkins Lymphoma - 11 July 2020
SSBMT Webinar Series - How I Treat Primary Myelofibrosis with Prof. Ayalew Tefferi - 4 July 2020
Webinar
SSBMT Webinar Series - How I Treat Primary Myelofibrosis with Prof. Ayalew Tefferi - 4 July 2020
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat Primary Myelofibrosis with Prof. Ayalew Tefferi - 4 July 2020
SSBMT Webinar Series - How I Treat? Primary Myelofibrosis - 04 July 2020
Webinar
SSBMT Webinar Series - How I Treat? Primary Myelofibrosis - 04 July 2020
Watched
Webinar
2020
SSBMT Webinar Series - How I Treat? Primary Myelofibrosis - 04 July 2020
SSBMT جمعية الخلايا الجذعية Live Stream
Live
SSBMT جمعية الخلايا الجذعية Live Stream
Watched
Live
2020
SSBMT جمعية الخلايا الجذعية Live Stream
SSBMT Webinar Series - Sickle Cell Disease Part 1 - May 13, 2020
Webinar
SSBMT Webinar Series - Sickle Cell Disease Part 1 - May 13, 2020
Watched
Webinar
2020
SSBMT Webinar Series - Sickle Cell Disease Part 1 - May 13, 2020
SSBMT Webinar Series - Sickle Cell Disease Part 2 - 16 May 2020
Webinar
SSBMT Webinar Series - Sickle Cell Disease Part 2 - 16 May 2020
Watched
Webinar
2020
SSBMT Webinar Series - Sickle Cell Disease Part 2 - 16 May 2020
SSBMT Webinar Series - Sickle Cell Disease Part 2 - 16 May 2020
Webinar
SSBMT Webinar Series - Sickle Cell Disease Part 2 - 16 May 2020
Watched
Webinar
2020
SSBMT Webinar Series - Sickle Cell Disease Part 2 - 16 May 2020
SSBMT Webinar Series - Sickle Cell Disease - May 13
Webinar
SSBMT Webinar Series - Sickle Cell Disease - May 13
Watched
Webinar
2020
SSBMT Webinar Series - Sickle Cell Disease - May 13
متبرعين بالخلايا الجذعية
General
متبرعين بالخلايا الجذعية
Watched
General
2019
متبرعين بالخلايا الجذعية
SSBMT جمعية الخلايا الجذعية
كيفية الانضمام إلى السجل السعودي للمتبرعين بالخلايا الجذعيه
General
كيفية الانضمام إلى السجل السعودي للمتبرعين بالخلايا الجذعيه
Watched
General
2019
كيفية الانضمام إلى السجل السعودي للمتبرعين بالخلايا الجذعيه
SSBMT جمعية الخلايا الجذعية
Saudi Lymphoma Myeloma 16 Current Paradigms on Management of Relapsed Multiple Myeloma
General
Saudi Lymphoma Myeloma 16 Current Paradigms on Management of Relapsed Multiple Myeloma
Watched
General
2018
Saudi Lymphoma Myeloma 16 Current Paradigms on Management of Relapsed Multiple Myeloma
Saudi Lymphoma Myeloma 15 DLBCL, Improving Outcome in High risk Disease
General
Saudi Lymphoma Myeloma 15 DLBCL, Improving Outcome in High risk Disease
Watched
General
2018
Saudi Lymphoma Myeloma 15 DLBCL, Improving Outcome in High risk Disease
Saudi Lymphoma Myeloma 14 Primary CNS lymphoma
General
Saudi Lymphoma Myeloma 14 Primary CNS lymphoma
Watched
General
2018
Saudi Lymphoma Myeloma 14 Primary CNS lymphoma
Saudi Lymphoma Myeloma 05 Geriatric Hematology in lymphoma
General
Saudi Lymphoma Myeloma 05 Geriatric Hematology in lymphoma
Watched
General
2018
Saudi Lymphoma Myeloma 05 Geriatric Hematology in lymphoma
Saudi Lymphoma Myeloma 13 Lymphoma in the era of precision Oncology
General
Saudi Lymphoma Myeloma 13 Lymphoma in the era of precision Oncology
Watched
General
2018
Saudi Lymphoma Myeloma 13 Lymphoma in the era of precision Oncology
Saudi Lymphoma Myeloma 12 Immunotherapy in Myeloma Past, Present & Future
General
Saudi Lymphoma Myeloma 12 Immunotherapy in Myeloma Past, Present & Future
Watched
General
2018
Saudi Lymphoma Myeloma 12 Immunotherapy in Myeloma Past, Present & Future
Saudi Lymphoma Myeloma 11 Burkitt’s Lymphoma, KAMC J
General
Saudi Lymphoma Myeloma 11 Burkitt’s Lymphoma, KAMC J
Watched
General
2018
Saudi Lymphoma Myeloma 11 Burkitt’s Lymphoma, KAMC J
Saudi Lymphoma Myeloma 10 WHO update of T cell lymphomas
General
Saudi Lymphoma Myeloma 10 WHO update of T cell lymphomas
Watched
General
2018
Saudi Lymphoma Myeloma 10 WHO update of T cell lymphomas
Saudi Lymphoma Myeloma 09 Satellite Symposia
General
Saudi Lymphoma Myeloma 09 Satellite Symposia
Watched
General
2018
Saudi Lymphoma Myeloma 09 Satellite Symposia
Saudi Lymphoma Myeloma 08 Advancement in MCL, WM and HCL
General
Saudi Lymphoma Myeloma 08 Advancement in MCL, WM and HCL
Watched
General
2018
Saudi Lymphoma Myeloma 08 Advancement in MCL, WM and HCL
Saudi Lymphoma Myeloma 07 ALL, KAMC R
General
Saudi Lymphoma Myeloma 07 ALL, KAMC R
Watched
General
2018
Saudi Lymphoma Myeloma 07 ALL, KAMC R
Saudi Lymphoma Myeloma 06 ASCT in MM patients KAMCR
General
Saudi Lymphoma Myeloma 06 ASCT in MM patients KAMCR
Watched
General
2018
Saudi Lymphoma Myeloma 06 ASCT in MM patients KAMCR
Saudi Lymphoma Myeloma 04 CLL, Risk adapted management
General
Saudi Lymphoma Myeloma 04 CLL, Risk adapted management
Watched
General
2018
Saudi Lymphoma Myeloma 04 CLL, Risk adapted management
Saudi Lymphoma Myeloma 03 Apostolidis
General
Saudi Lymphoma Myeloma 03 Apostolidis
Watched
General
2018
Saudi Lymphoma Myeloma 03 Apostolidis
Saudi Lymphoma Myeloma 02 Overview
General
Saudi Lymphoma Myeloma 02 Overview
Watched
General
2018
Saudi Lymphoma Myeloma 02 Overview
Saudi Lymphoma Myeloma 01 Opening Remarks
General
Saudi Lymphoma Myeloma 01 Opening Remarks
Watched
General
2018
Saudi Lymphoma Myeloma 01 Opening Remarks
التبرع بدم الحبل السري
General
التبرع بدم الحبل السري
Watched
General
2018
التبرع بدم الحبل السري
جائزة الإنجاز المهني في أمراض الدم من الجمعية السعودية الخلايا الجذعية
General
جائزة الإنجاز المهني في أمراض الدم من الجمعية السعودية الخلايا الجذعية
Watched
General
2018
جائزة الإنجاز المهني في أمراض الدم من الجمعية السعودية الخلايا الجذعية
SSBMT جمعية الخلايا الجذعية
نبذة عن الجمعية السعودية لزراعة الخلايا الجذعية ٢٠١٨
General
نبذة عن الجمعية السعودية لزراعة الخلايا الجذعية ٢٠١٨
Watched
General
2018
نبذة عن الجمعية السعودية لزراعة الخلايا الجذعية ٢٠١٨
SSBMT جمعية الخلايا الجذعية
ssbmt motion graphics
General
ssbmt motion graphics
Watched
General
2018
ssbmt motion graphics
SSBMT جمعية الخلايا الجذعية